

546,005

Rec'd PCT/PTO 18 AUG 2005

10 546 005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/076430 A1

(51) International Patent Classification⁷: **C07D 281/10**,
337/08, A61K 31/38, 31/554, A61P 3/06

(21) International Application Number:
PCT/GB2004/000695

(22) International Filing Date: 23 February 2004 (23.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0304194.4 25 February 2003 (25.02.2003) GB

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; Sodertalje, SE-151 85 (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STARKE, Ingemar** [SE/SE]; Astrazeneca R & d Molndal, SE-431 83 Molndal (SE). **ALENFALK, Suzanne** [SE/SE]; Astrazeneca R & d Molndal, SE-431 83 Molndal (SE). **NORDBERG, Mats, Peter** [SE/SE]; Astrazeneca R & d Molndal, SE-431 83 Molndal (SE). **DAHLSTROM, Mikael, Ulf, Johan** [FI/SE]; Astrazeneca R & d Molndal, SE-431 83 Molndal (SE). **BOSTROM, Stig, Jonas** [SE/SE]; Astrazeneca R & d Molndal, SE-431 83 Molndal (SE). **LEMURELL, Malin, Anita** [SE/SE]; Astrazeneca R & d Molndal, SE-431 83 Molndal (SE). **WALLBERG, Andreas, Christer** [SE/SE]; Astrazeneca R & d Molndal, SE-431 83 Molndal (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, P O Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **BENZOTHIAZEPINE AND BENZOTHIOPINE DERIVATIVES**

(57) Abstract: Compounds of formula: (I) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

WO 2004/076430 A1

BENZOTHIAZEPINE AND BENZOTHIPIEPINE DERIVATIVES

This invention relates to benzothiazepine and benzothieline derivatives, or pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof. These
5 benzothiazepines and benzothielines possess ileal bile acid transport (IBAT) inhibitory activity and accordingly have value in the treatment of disease states associated with hyperlipidaemic conditions and they are useful in methods of treatment of a warm-blooded animal, such as man. The invention also relates to processes for the manufacture of said benzothiazepine and benzothieline derivatives, to pharmaceutical compositions containing
10 them and to their use in the manufacture of medicaments to inhibit IBAT in a warm-blooded animal, such as man.

It is well-known that hyperlipidaemic conditions associated with elevated concentrations of total cholesterol and low-density lipoprotein cholesterol are major risk factors for cardiovascular atherosclerotic disease (for instance "Coronary Heart Disease:
15 Reducing the Risk; a Worldwide View" Assman G., Carmena R. Cullen P. *et al*; Circulation 1999, 100, 1930-1938 and "Diabetes and Cardiovascular Disease: A Statement for Healthcare Professionals from the American Heart Association" Grundy S, Benjamin I., Burke G., *et al*; Circulation, 1999, 100, 1134-46). Interfering with the circulation of bile acids within the lumen of the intestinal tracts is found to reduce the level of cholesterol. Previous established
20 therapies to reduce the concentration of cholesterol involve, for instance, treatment with HMG-CoA reductase inhibitors, preferably statins such as simvastatin and fluvastatin, or treatment with bile acid binders, such as resins. Frequently used bile acid binders are for instance cholestyramine and cholestipol. One recently proposed therapy ("Bile Acids and Lipoprotein Metabolism: a Renaissance for Bile Acids in the Post Statin Era" Angelin B,
25 Eriksson M, Rudling M; Current Opinion on Lipidology, 1999, 10, 269-74) involved the treatment with substances with an IBAT inhibitory effect.


Re-absorption of bile acid from the gastro-intestinal tract is a normal physiological process which mainly takes place in the ileum by the IBAT mechanism. Inhibitors of IBAT can be used in the treatment of hypercholesterolaemia (see for instance "Interaction of bile
30 acids and cholesterol with nonsystemic agents having hypocholesterolaemic properties", Biochemica et Biophysica Acta, 1210 (1994) 255- 287). Thus, suitable compounds having such inhibitory IBAT activity are also useful in the treatment of hyperlipidaemic conditions. Substituted compounds possessing such IBAT inhibitory activity have been described, see for

instance hypolipidaemic compounds described in WO 93/16055, WO 94/18183, WO 94/18184, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO 98/38182, WO 99/35135, WO 98/40375, WO 99/64409, WO 99/64410, WO 00/01687, WO 00/47568, WO 00/61568, DE 19825804, WO 00/38725, WO 00/38726, WO 00/38727, WO 00/38728, WO 5 00/38729, WO01/68096, WO 01/66533, WO 02/50051, WO 03/020710, WO 03/022825, WO 03/022830, WO 03/022286 and EP 0 864 582.

A further aspect of this invention relates to the use of the compounds of the invention in the treatment of dyslipidemic conditions and disorders such as hyperlipidaemia, hypertriglyceridemia, hyperbetalipoproteinemia (high LDL), hyperprebetalipoproteinemia 10 (high VLDL), hyperchylomicronemia, hypolipoproteinemia, hypercholesterolemia, hyperlipoproteinemia and hypoalphalipoproteinemia (low HDL). In addition, these compounds are expected to be useful for the prevention and treatment of different clinical conditions such as atherosclerosis, arteriosclerosis, arrhythmia, hyper-thrombotic conditions, vascular dysfunction, endothelial dysfunction, heart failure, coronary heart diseases, 15 cardiovascular diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, inflammation of cardiovascular tissues such as heart, valves, vasculature, arteries and veins, aneurisms, stenosis, restenosis, vascular plaques, vascular fatty streaks, leukocytes, monocytes and/or macrophage infiltration, intimal thickening, medial thinning, infectious and surgical trauma and vascular thrombosis, stroke and transient ischaemic attacks.

20 The present invention is based on the discovery that certain benzothiazepine and benzothiepine compounds surprisingly inhibit IBAT. Such properties are expected to be of value in the treatment of disease states associated with hyperlipidaemic conditions.

Accordingly, the present invention provides a compound of formula (I):



(I)

25

wherein

M^1 is $-CH_2-$ or $-NR^{21}-$;


M^2 is $-CR^{22}R^{23}-$ or $-NR^{24}-$; provided that if M^1 is $-NR^{21}-$, M^2 is $-CR^{22}R^{23}-$;

One of R^1 and R^2 are selected from hydrogen, C_{1-6} alkyl or C_{2-6} alkenyl and the other is selected from C_{1-6} alkyl or C_{2-6} alkenyl;

5 R^3 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, $N-(C_{1-6}alkyl)amino$, $N,N-(C_{1-6}alkyl)_2amino$, $C_{1-6}alkanoylamino$, $N-(C_{1-6}alkyl)carbamoyl$, $N,N-(C_{1-6}alkyl)_2carbamoyl$, $C_{1-6}alkylS(O)_a$ wherein a is 0 to 2, $C_{1-6}alkoxycarbonyl$, $N-(C_{1-6}alkyl)sulphamoyl$ and $N,N-(C_{1-6}alkyl)_2sulphamoyl$;

10 v is 0-5;

one of R^5 and R^6 is a group of formula (IA):



(IA)

R^4 and R^7 and the other of R^5 and R^6 are independently selected from hydrogen, halo, 15 nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, $N-(C_{1-4}alkyl)amino$, $N,N-(C_{1-4}alkyl)_2amino$, $C_{1-4}alkanoylamino$, $N-(C_{1-4}alkyl)carbamoyl$, $N,N-(C_{1-4}alkyl)_2carbamoyl$, $C_{1-4}alkylS(O)_a$ wherein a is 0 to 2, $C_{1-4}alkoxycarbonyl$, $N-(C_{1-4}alkyl)sulphamoyl$ and $N,N-(C_{1-4}alkyl)_2sulphamoyl$; wherein R^4 and R^7 and the other of 20 R^5 and R^6 may be optionally substituted on carbon by one or more R^{25} ;

Z is $-O-$, $-N(R^a)-$, $-S(O)_b-$ or $-CH(R^a)-$; wherein R^a is hydrogen or C_{1-6} alkyl and b is 0-2;

R^8 is hydrogen, C_{1-4} alkyl, carbocyclyl or heterocyclyl; wherein R^8 may be optionally substituted on carbon by one or more substituents selected from R^{26} ; and wherein if said 25 heterocyclyl contains an $-NH-$ group, that nitrogen may be optionally substituted by a group selected from R^{27} ;


R^9 is hydrogen or C_{1-4} alkyl;

R^{10} and R^{11} are independently selected from hydrogen, C_{1-4} alkyl, carbocyclyl or heterocyclyl; or R^{10} and R^{11} together form $C_{2-6}alkylene$; wherein R^{10} and R^{11} or R^{10} and R^{11} 30 together may be independently optionally substituted on carbon by one or more substituents

selected from R^{28} ; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by one or more R^{29} ;

R^{12} is hydrogen, C_{1-4} alkyl, carbocyclyl or heterocyclyl; wherein R^{12} may be optionally substituted on carbon by one or more substituents selected from R^{30} ; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by one or more R^{31} ;

R^{13} is hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkoxycarbonyl, C_{1-10} alkanoyl, C_{1-10} alkanoyloxy, N -(C_{1-10} alkyl)amino, N,N -(C_{1-10} alkyl)₂amino, N,N,N -(C_{1-10} alkyl)₃ammonio, C_{1-10} alkanoylamino, N -(C_{1-10} alkyl)carbamoyl, N,N -(C_{1-10} alkyl)₂carbamoyl, C_{1-10} alkylS(O)_a wherein a is 0 to 2, N -(C_{1-10} alkyl)sulphamoyl, N,N -(C_{1-10} alkyl)₂sulphamoyl, N -(C_{1-10} alkyl)sulphamoylamino, N,N -(C_{1-10} alkyl)₂sulphamoylamino, C_{1-10} alkoxycarbonylamino, carbocyclyl, carbocyclyl C_{1-10} alkyl, heterocyclic group, heterocyclyl C_{1-10} alkyl, carbocyclyl-(C_{1-10} alkylene)_e- R^{32} -(C_{1-10} alkylene)_f or heterocyclyl-(C_{1-10} alkylene)_g- R^{33} -(C_{1-10} alkylene)_h; wherein R^{13} may be optionally substituted on carbon by one or more substituents selected from R^{36} ; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{37} ; or R^{13} is a group of formula (IB):



(IB)

wherein:

X is $-N(R^{38})-$, $-N(R^{38})C(O)-$, $-O-$, and $-S(O)_a-$; wherein a is 0-2 and R^{38} is hydrogen or C_{1-4} alkyl;


R^{14} is hydrogen or C_{1-4} alkyl;

R^{15} and R^{16} are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a

wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl,

carbocyclyl or heterocyclic group; wherein R^{15} and R^{16} may be independently optionally substituted on carbon by one or more substituents selected from R^{41} ; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{42} ;

- 5 R^{17} is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkanoyl, C_{1-10} alkanoyloxy, N -(C_{1-10} alkyl)amino, N,N -(C_{1-10} alkyl)₂amino, C_{1-10} alkanoylamino, N -(C_{1-10} alkyl)carbamoyl, C_{1-10} alkoxycarbonyl, N,N -(C_{1-10} alkyl)₂carbamoyl, C_{1-10} alkylS(O)_a wherein a is 0 to 2, N -(C_{1-10} alkyl)sulphamoyl, 10 N,N -(C_{1-10} alkyl)₂sulphamoyl, N -(C_{1-10} alkyl)sulphamoylamino, N,N -(C_{1-10} alkyl)₂sulphamoylamino, carbocyclyl, carbocyclyl C_{1-10} alkyl, heterocyclic group, heterocyclyl C_{1-10} alkyl, carbocyclyl-(C_{1-10} alkylene)_e- R^{43} -(C_{1-10} alkylene)_f or heterocyclyl-(C_{1-10} alkylene)_g- R^{44} -(C_{1-10} alkylene)_h-; wherein R^{17} may be optionally substituted on carbon by one or more substituents selected from R^{47} ; and wherein if said heterocyclyl 15 contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{48} ; or R^{17} is a group of formula (IC):



(IC)

wherein:

- 20 R^{18} is selected from hydrogen or C_{1-4} alkyl;
 R^{19} is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, 25 C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, carbocyclyl or heterocyclic group; where R^{19} may be independently optionally substituted on carbon by one or more substituents selected from R^{51} ; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{52} ;
 R^{20} is selected from halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, 30 sulphamoyl, hydroxyaminocarbonyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy,

- C_{1-10} alkoxycarbonyl, C_{1-10} alkanoyl, C_{1-10} alkanoyloxy, N -(C_{1-10} alkyl)amino,
 N,N -(C_{1-10} alkyl) $_2$ amino, N,N,N -(C_{1-10} alkyl) $_3$ ammonio, C_{1-10} alkanoylamino,
 N -(C_{1-10} alkyl)carbamoyl, N,N -(C_{1-10} alkyl) $_2$ carbamoyl, C_{1-10} alkylS(O) $_a$ wherein a is 0 to 2,
 N -(C_{1-10} alkyl)sulphamoyl, N,N -(C_{1-10} alkyl) $_2$ sulphamoyl, N -(C_{1-10} alkyl)sulphamoylamino,
5 N,N -(C_{1-10} alkyl) $_2$ sulphamoylamino, C_{1-10} alkoxycarbonylamino, carbocyclyl,
carbocyclyl C_{1-10} alkyl, heterocyclic group, heterocyclyl C_{1-10} alkyl,
carbocyclyl-(C_{1-10} alkylene) $_e$ -R⁵³-(C_{1-10} alkylene) $_f$ or
heterocyclyl-(C_{1-10} alkylene) $_g$ -R⁵⁴-(C_{1-10} alkylene) $_h$; wherein R²⁰ may be independently
optionally substituted on carbon by one or more R⁵⁷; and wherein if said heterocyclyl contains
10 an -NH- group, that nitrogen may be optionally substituted by a group selected from R⁵⁸;

p is 1-3; wherein the values of R¹⁵ may be the same or different;
 q is 0-1;
 r is 0-3; wherein the values of R¹⁶ may be the same or different;
 m is 0-2; wherein the values of R¹² may be the same or different;
15 n is 1-2; wherein the values of R⁸ may be the same or different;
 z is 0-3; wherein the values of R¹⁹ may be the same or different;
R²¹ is selected from hydrogen or C_{1-6} alkyl;
R²² and R²³ are independently selected from hydrogen, hydroxy, amino, mercapto,
 C_{1-6} alkyl, C_{1-6} alkoxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkylS(O) $_a$ wherein a is
20 0 to 2;
R²⁴ is selected from hydrogen, hydroxy, C_{1-6} alkyl, C_{1-4} alkoxy and C_{1-6} alkanoyloxy;
R²⁵ is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto,
sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy,
 N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl) $_2$ amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl,
25 N,N -(C_{1-4} alkyl) $_2$ carbamoyl, C_{1-4} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-4} alkoxycarbonyl,
 N -(C_{1-4} alkyl)sulphamoyl and N,N -(C_{1-4} alkyl) $_2$ sulphamoyl; wherein R²⁵, may be independently
optionally substituted on carbon by one or more R⁶⁷;
R²⁶, R²⁸, R³⁰, R³⁶, R⁴¹, R⁴⁷, R⁵¹ and R⁵⁷ are independently selected from halo, nitro,
cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C_{1-10} alkyl,
30 C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkanoyl, C_{1-10} alkanoyloxy, C_{1-10} alkoxycarbonyl,
 N -(C_{1-10} alkyl)amino, N,N -(C_{1-10} alkyl) $_2$ amino, N,N,N -(C_{1-10} alkyl) $_3$ ammonio,
 C_{1-10} alkanoylamino, N -(C_{1-10} alkyl)carbamoyl, N,N -(C_{1-10} alkyl) $_2$ carbamoyl, C_{1-10} alkylS(O) $_a$

wherein a is 0 to 2, *N*-(C₁₋₁₀alkyl)sulphamoyl, *N,N*-(C₁₋₁₀alkyl)₂sulphamoyl, *N*-(C₁₋₁₀alkyl)sulphamoylamino, *N,N*-(C₁₋₁₀alkyl)₂sulphamoylamino, C₁₋₁₀alkoxycarbonylamino, carbocyclyl, carbocyclylC₁₋₁₀alkyl, heterocyclic group, heterocyclylC₁₋₁₀alkyl, carbocyclyl-(C₁₋₁₀alkylene)_e-R⁵⁹-(C₁₋₁₀alkylene)_f or
 5 heterocyclyl-(C₁₋₁₀alkylene)_g-R⁶⁰-(C₁₋₁₀alkylene)_h-; wherein R²⁶, R²⁸, R³⁰, R³⁶, R⁴¹, R⁴⁷, R⁵¹ and R⁵⁷ may be independently optionally substituted on carbon by one or more R⁶³; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R⁶⁴;

R²⁷, R²⁹, R³¹, R³⁷, R⁴², R⁴⁸, R⁵², R⁵⁸ and R⁶⁴ are independently selected from
 10 C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, sulphamoyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, benzyl, phenethyl, benzoyl, phenylsulphonyl and phenyl;

R³², R³³, R⁴³, R⁴⁴, R⁵³, R⁵⁴, R⁵⁹ and R⁶⁰ are independently selected from -O-, -NR⁶⁵-, -S(O)_x-, -NR⁶⁵C(O)NR⁶⁶-, -NR⁶⁵C(S)NR⁶⁶-, -OC(O)N=C-, -NR⁶⁵C(O)- or -C(O)NR⁶⁵-;
 15 wherein R⁶⁵ and R⁶⁶ are independently selected from hydrogen or C₁₋₆alkyl, and x is 0-2;

R⁶³ and R⁶⁷ are independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxymethyl, methylamino, dimethylamino, *N*-methylcarbamoyl,
 20 *N,N*-dimethylcarbamoyl, methylthio, methylsulphinyl, mesyl, *N*-methylsulphamoyl and *N,N*-dimethylsulphamoyl; and

e, f, g and h are independently selected from 0-2;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

In this specification the term "alkyl" includes both straight and branched chain alkyl
 25 groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C₁₋₁₀alkyl" and "C₁₋₆alkyl" includes C₁₋₄alkyl, C₁₋₃alkyl, propyl, isopropyl and *t*-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar
 30 convention applies to other radicals, for example "phenylC₁₋₆alkyl" would include phenylC₁₋₆alkyl, benzyl, 1-phenylethyl and 2-phenylethyl. The term "halo" refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic
5 ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form the S-oxides. Preferably a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is
10 chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form S-oxide(s). Examples and suitable values of the term "heterocyclyl" are thiazolidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2,5-dioxopyrrolidinyl, 2-benzoxazolinonyl, 1,1-dioxotetrahydrothienyl,
15 2,4-dioxoimidazolidinyl, 2-oxo-1,3,4-(4-triazolinyl), 2-oxazolidinonyl, 5,6-dihydrouracilyl, 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, 4-thiazolidonyl, morpholino, 2-oxotetrahydrofuranyl, tetrahydrofuranyl, 2,3-dihydrobenzofuranyl, benzothienyl, tetrahydropyranyl, piperidyl, 1-oxo-1,3-dihydroisoindolyl, piperazinyl, thiomorpholino, 1,1-dioxothiomorpholino, tetrahydropyranyl, 1,3-dioxolanyl, homopiperazinyl, thienyl,
20 isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, pyranlyl, indolyl, pyrimidyl, thiazolyl, pyrazinyl, pyridazinyl, pyridyl, 4-pyridonyl, quinolyl and 1-isoquinolonyl.

A "heterocyclic group" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen,
25 sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form the S-oxides. A "heterocyclic group" is not tetrazolyl. Preferably a "heterocyclic group" is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms of which at least one atom
30 is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form S-oxide(s). Examples and suitable values of the term "heterocyclic group" are thiazolidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl,

2,5-dioxopyrrolidinyl, 2-benzoxazolinonyl, 1,1-dioxotetrahydrothienyl,
 2,4-dioxoimidazolidinyl, 2-oxo-1,3,4-(4-triazoliny), 2-oxazolidinonyl, 5,6-dihydrouracilyl,
 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, 4-thiazolidonyl, morpholino,
 2-oxotetrahydrofuranlyl, tetrahydrofuranlyl, 2,3-dihydrobenzofuranlyl, benzothienyl,
 5 tetrahydropyranlyl, piperidyl, 1-oxo-1,3-dihydroisoindolyl, piperazinyl, thiomorpholino,
 1,1-dioxothiomorpholino, tetrahydropyranlyl, 1,3-dioxolanyl, homopiperazinyl, thienyl,
 isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl,
 pyranlyl, indolyl, pyrimidyl, thiazolyl, pyrazinyl, pyridazinyl, pyridyl, 4-pyridonyl, quinolyl
 and 1-isoquinolonyl.

- 10 A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH₂- group can optionally be replaced by a -C(O)-. Preferably "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl,
 15 naphthyl, tetralinyl, indanyl or 1-oxoindanyl. Particularly "carbocyclyl" is cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl or 1-oxoindanyl.

- An example of "C₁₋₁₀alkanoyloxy" and "C₁₋₆alkanoyloxy" is acetoxyl. Examples of "C₁₋₁₀alkoxycarbonyl" and "C₁₋₆alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl,
 20 *n*- and *t*-butoxycarbonyl. Examples of "C₁₋₁₀alkoxy" and "C₁₋₆alkoxy" include methoxy, ethoxy and propoxy. Examples of "C₁₋₁₀alkanoylamino" and "C₁₋₆alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C₁₋₆alkanoyl-*N*-(C₁₋₆alkyl)amino" include acetyl-*N*-methylamino and propionyl-*N*-ethyl-amino. Examples of "C₁₋₁₀alkylS(O)_a wherein a is 0 to 2" and "C₁₋₆alkylS(O)_a wherein a is 0 to 2" include methylthio, ethylthio,
 25 methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C₁₋₁₀alkanoyl" and "C₁₋₆alkanoyl" include C₁₋₃alkanoyl, propionyl and acetyl. Examples of "*N*-(C₁₋₁₀alkyl)amino" and "*N*-(C₁₋₆alkyl)amino" include methylamino and ethylamino. Examples of "*N,N*-(C₁₋₁₀alkyl)₂amino" and "*N,N*-(C₁₋₆alkyl)₂amino" include di-*N*-methylamino, di-(*N*-ethyl)amino and *N*-ethyl-*N*-methylamino. Examples of "C₂₋₁₀alkenyl" and "C₂₋₆alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C₂₋₁₀alkynyl" and "C₂₋₆alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "C₂₋₆alkylene" are ethylene, propylene and butylene. Examples of "C₂₋₆alkenyloxy" are vinyloxy, allyloxy and 1-propenyloxy. Examples of "*N*-(C₁₋₁₀alkyl)sulphamoyl" and "*N*-(C₁₋₆alkyl)sulphamoyl" are *N*-(C₁₋₃alkyl)sulphamoyl,

- N*-(methyl)sulphamoyl and *N*-(ethyl)sulphamoyl. Examples of "*N*-(C₁₋₁₀alkyl)₂sulphamoyl" and "*N*-(C₁₋₆alkyl)₂sulphamoyl" are *N,N*-(dimethyl)sulphamoyl and *N*-(methyl)-*N*-(ethyl)sulphamoyl. Examples of "*N*-(C₁₋₁₀alkyl)carbamoyl" and "*N*-(C₁₋₆alkyl)carbamoyl" are methylaminocarbonyl and ethylaminocarbonyl. Examples of
- 5 "*N,N*-(C₁₋₁₀alkyl)₂carbamoyl" and "*N,N*-(C₁₋₆alkyl)₂carbamoyl" are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "*N*-(C₁₋₁₀alkyl)carbamoyl" and "*N*-(C₁₋₆alkyl)carbamoxyloxy" are methylaminocarbonyloxy and ethylaminocarbonyloxy. Examples of "*N,N*-(C₁₋₁₀alkyl)₂carbamoxyloxy" and "*N,N*-(C₁₋₆alkyl)₂carbamoxyloxy" are dimethylaminocarbonyloxy and methylethylaminocarbonyloxy. Examples of
- 10 "C₁₋₆alkylsulphonyl" are mesyl and ethylsulphonyl. Examples of "C₁₋₁₀alkylsulphonylamino" and "C₁₋₆alkylsulphonylamino" are mesylamino and ethylsulphonylamino. Examples of "C₁₋₆alkylsulphonyl-*N*-(C₁₋₆alkyl)amino" are mesyl-*N*-methylamino and ethylsulphonyl-*N*-propylamino. Examples of "*N'*-(C₁₋₆alkyl)ureido" are *N'*-methylureido and *N'*-*i*-propylureido. Examples of "*N*-(C₁₋₆alkyl)ureido" are *N*-methylureido and *N*-*i*-propylureido. Examples of
- 15 "*N',N'*-(C₁₋₆alkyl)₂ureido" are *N',N'*-dimethylureido and *N'*-methyl-*N'*-ethylureido. Examples of "*N'*-(C₁₋₆alkyl)-*N*-(C₁₋₆alkyl)ureido" are *N',N*-dimethylureido and *N'*-methyl-*N*-ethylureido. Examples of "*N',N'*-(C₁₋₆alkyl)₂-*N*-(C₁₋₆alkyl)ureido" are *N',N'*-dimethyl-*N*-methylureido and *N'*-methyl-*N'*-ethyl-*N*-*t*-butylureido. Examples of "*N,N,N*-(C₁₋₁₀alkyl)₃ammonio" are trimethylamino and methyldiethylamino. Examples of "C₁₋₁₀alkoxycarbonylamino" and
- 20 "C₁₋₆alkoxycarbonylamino" are methoxycarbonylamino and *t*-butoxycarbonylamino. Examples of "*N*-(C₁₋₁₀alkyl)sulphamoylamino" are *N*-methylsulphamoylamino and *N*-ethylsulphamoylamino. Examples of "*N,N*-(C₁₋₁₀alkyl)₂sulphamoylamino" are *N,N*-dimethylsulphamoylamino and *N*-methyl-*N*-ethylsulphamoylamino. Examples of "carbocyclylC₁₋₁₀alkyl" include benzyl and phenethyl. Examples of "heterocyclylC₁₋₁₀alkyl"
- 25 include 2-morpholinopropyl and pyridylmethyl. Examples of "phenylC₁₋₆alkoxy" include 2-phenylethoxy and 2-phenylpropoxy.

A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example

30 hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric, acetate or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt

with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

The compounds of the formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I).
5 examples of pro-drugs include *in vivo* hydrolysable esters and *in vivo* hydrolysable amides of a compound of the formula (I).

An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically
10 acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and
15 C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

An *in vivo* hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the
20 parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyle and
N-(dialkylaminoethyl)-N-alkylcarbamoyle (to give carbamates), dialkylaminoacetyl and
25 carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.

A suitable value for an *in vivo* hydrolysable amide of a compound of the formula (I) containing a carboxy group is, for example, a N-C₁₋₆alkyl or N,N-di-C₁₋₆alkyl amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethyl amide.

30 Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess IBAT inhibitory activity.

The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess IBAT inhibitory activity.

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess IBAT inhibitory activity.

Particular values are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

M^1 is $-\text{CH}_2-$.

10 M^1 is $-\text{NR}^{21}-$.

M^2 is $-\text{CR}^{22}\text{R}^{23}-$.

M^2 is $-\text{NR}^{24}-$.

M^1 is $-\text{CH}_2-$ and M^2 is $-\text{CR}^{22}\text{R}^{23}-$.

M^1 is $-\text{CH}_2-$ and M^2 is $-\text{NR}^{24}-$.

15 M^1 is $-\text{NR}^{21}-$ and M^2 is $-\text{CR}^{22}\text{R}^{23}-$.

R^{21} is hydrogen.

R^{21} is C_{1-6} alkyl.

R^{22} and R^{23} are independently selected from hydrogen and hydroxy.

One of R^{22} and R^{23} is hydrogen and the other is hydroxy.

20 R^{24} is hydrogen.

R^1 and R^2 are C_{1-4} alkyl.

R^1 and R^2 are both butyl.

One of R^1 and R^2 is ethyl and the other is butyl.

v is 0.

25 R^3 is C_{1-4} alkyl.

R^5 is a group of formula (IA).

R^6 is a group of formula (IA).

R^4 and R^7 are hydrogen.

R^5 is methylthio and R^6 is a group of formula (IA).

30 The R^5 or R^6 not selected from a group of formula (IA) is hydrogen, halo, C_{1-4} alkyl or C_{1-4} alkyl $\text{S}(\text{O})_a$ wherein a is 0.

The R⁵ or R⁶ not selected from a group of formula (IA) is hydrogen, bromo, methyl or methylthio.

The R⁵ or R⁶ not selected from a group of formula (IA) is hydrogen or methylthio.

The R⁵ or R⁶ not selected from a group of formula (IA) is hydrogen.

5 The R⁵ or R⁶ not selected from a group of formula (IA) is methylthio.

The group of formula (IA) is selected from:

N-{(R)- α -[N'-(2-hydroxyethyl)carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-(2-trimethylaminoethyl)carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-(2-aminoethyl)carbamoyl]benzyl}carbamoylmethoxy;

10 *N*-{(R)- α -[N'-(carbamoylmethyl)carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-((S)-1-carbamoyl-2-hydroxyethyl)carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -carbamoylbenzyl}carbamoylmethoxy;

N-{(R)- α -[N'-(1,1-di-hydroxymethyl-2-hydroxyethyl)carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-(hydroxycarbamoylmethyl)carbamoyl]benzyl}carbamoylmethoxy;

15 *N*-{(R)- α -[N'-[N-(2,2,2-trifluoroethyl)carbamoylmethyl]carbamoyl]benzyl}

carbamoylmethoxy;

N-{(R)- α -[N'-[N-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoylmethyl]carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-[N-(2-fluoroethyl)carbamoylmethyl]carbamoyl]benzyl}carbamoylmethoxy;

20 *N*-{(R)- α -[N'-[N-(ethyl)carbamoylmethyl]carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-[N-(4-hydroxy-3-methoxybenzyl)carbamoylmethyl]carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-[N-(2-methoxyethyl)carbamoylmethyl]carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-[N-(4-sulphamoylphenethyl)carbamoylmethyl]carbamoyl]benzyl}

25 carbamoylmethoxy;

N-{(R)- α -[N'-[N-(2-*N,N*-dimethylaminosulphamoyl)ethyl]carbamoylmethyl]carbamoyl}benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-[N-(2-(N'-pyrimidin-2-ylureido)ethyl)carbamoylmethyl]carbamoyl]benzyl}carbamoylmethoxy;

30 *N*-{(R)- α -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy;

N-{(R)- α -[N'-(3-morpholinopropyl)carbamoyl]benzyl}carbamoylmethoxy;

- N*-{(R)- α -[*N*-(2-imidazol-4-ylethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(2-*N,N*-dimethylaminosulphamoyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(2-(2-hydroxyphenoxy)ethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(3-hydroxy-1,5-benzodioxepin-3-yl)methyl]carbamoyl]benzyl}
 5 carbamoylmethoxy;
N-{(R)- α -[*N*-(3-*t*-butoxycarbonylaminobenzyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(3-(benzyloxycarbonylimino-1-aminomethyl)benzyl)carbamoyl]benzyl}
 carbamoylmethoxy;
N-{(R)- α -[*N*-(2-(3,4-dihydroxyphenyl)-2-methoxyethyl)carbamoyl]benzyl}
 10 carbamoylmethoxy;
N-{(R)- α -[*N*-(2,3-dihydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(2-(5-methoxyindol-3-yl)ethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(2-(2,5-dioxothiazolidin-1-yl)ethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(3-(4-methylpiperazin-1-yl)propyl)carbamoyl]benzyl}carbamoylmethoxy;
 15 *N*-{(R)- α -[*N*-(4-sulphamoylphenethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(5,6-dimethoxy-2,3-dihydrobenzofuran-2-yl)methyl]carbamoyl]benzyl}
 carbamoylmethoxy;
N-{(R)- α -[*N*-(1-*t*-butoxycarbonylpiperidin-4-yl)methyl]carbamoyl]benzyl}
 carbamoylmethoxy;
 20 *N*-{(R)- α -[*N*-(4-nitroanilincarbonylmethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(2-(*N*-pyrimidin-2-ylureido)ethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(2-(*N*-pyridin-2-ylureido)ethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(2-(4-carbamoylphenoxy)ethyl)carbamoyl]benzyl}carbamoylmethoxy;
N-{(R)- α -[*N*-(2-(2-oxoimidazolidin-1-yl)ethyl)carbamoyl]benzyl}carbamoylmethoxy; and
 25 *N*-{(R)- α -[*N*-(3-aminobenzyl)carbamoyl]benzyl}carbamoylmethoxy.

The group of formula (IA) is selected from:

- N*-{ α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-2-fluorobenzyl}
 carbamoylmethylthio;
N-{1-[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-1-(cyclohexyl)
 30 methyl}carbamoylmethylthio;
N-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}
 carbamoylmethoxy;

N-[(R)- α -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl} carbamoylmethoxy.

Z is -O- or -S(O)_b-; wherein b is 0.

R⁸ is hydrogen.

5 R⁹ is hydrogen.

R¹⁰ and R¹¹ are independently selected from hydrogen or carbocyclyl; wherein R¹⁰ and R¹¹ may be independently optionally substituted on carbon by one or more substituents selected from R²⁸.

10 R¹⁰ and R¹¹ are independently selected from hydrogen, cyclohexyl or phenyl; wherein R¹⁰ and R¹¹ may be independently optionally substituted on carbon by one or more substituents selected from halo.

R¹⁰ and R¹¹ are independently selected from hydrogen, cyclohexyl or 2-fluorophenyl.

R¹³ is a group of formula (IB).

R¹⁴ is hydrogen.

15 R¹⁵ is hydrogen.

R¹⁷ is C₁₋₁₀alkyl; wherein R¹⁷ may be optionally substituted on carbon by one or more substituents selected from R⁴⁷ or R¹⁷ is a group of formula (IC) (as depicted above).

R¹⁷ is C₁₋₁₀alkyl; wherein R¹⁷ may be optionally substituted on carbon by one or more substituents selected from R⁴⁷ or R¹⁷ is a group of formula (IC) (as depicted above).

20 R¹⁷ is C₁₋₆alkyl; wherein R¹⁷ may be optionally substituted on carbon by one or more hydroxy or R¹⁷ is a group of formula (IC) (as depicted above).

R¹⁷ is pentyl substituted by 5 hydroxy or R¹⁷ is a group of formula (IC) (as depicted above).

R¹⁸ is selected from hydrogen.

25 R¹⁹ is selected from hydrogen.

R²⁰ is C₁₋₁₀alkyl; wherein R²⁰ may be independently optionally substituted on carbon by one or more R⁵⁷.

R²⁰ is C₁₋₁₀alkyl; wherein R²⁰ may be independently optionally substituted on carbon by one or more hydroxy.

30 R²⁰ is pentyl substituted by 5 hydroxy.

p is 1.

q is 0.

r is 0.

m is 0.

n is 1.

z is 1.

5 R^{28} is halo.

R^{28} is fluoro.

R^{47} is hydroxy.

R^{57} is hydroxy.

One of R^5 and R^6 is a group of formula (IA) (as depicted above); wherein:

10 Z is -O- or -S(O)_b-; wherein b is 0;

R^8 is hydrogen;

R^9 is hydrogen;

R^{10} and R^{11} are independently selected from hydrogen or carbocyclyl; wherein R^{10} and

R^{11} may be independently optionally substituted on carbon by one or more substituents

15 selected from R^{28} ;

R^{13} is a group of formula (IB) (as depicted above);

R^{14} is hydrogen;

R^{15} is hydrogen;

R^{17} is C₁₋₁₀alkyl; wherein R^{17} may be optionally substituted on carbon by one or more

20 substituents selected from R^{47} ; or R^{17} is a group of formula (IC) (as depicted above) wherein:

R^{18} is selected from hydrogen;

R^{19} is selected from hydrogen;

R^{20} is C₁₋₁₀alkyl; wherein R^{20} may be independently optionally substituted on carbon

by one or more R^{57} ;

25 p is 1;

q is 0;

r is 0;

m is 0;

n is 1;

30 z is 1; and

R^{28} , R^{47} and R^{57} are independently selected from halo and hydroxy.

One of R^5 and R^6 is a group of formula (IA) (as depicted above); wherein:

Z is -O- or -S(O)_b-; wherein b is 0;

R⁸ is hydrogen;

R⁹ is hydrogen;

R¹⁰ and R¹¹ are independently selected from hydrogen, phenyl or carbocyclyl; wherein

5 R¹⁰ and R¹¹ may be independently optionally substituted on carbon by one or more substituents selected from halo;

R¹³ is a group of formula (IB) (as depicted above);

R¹⁴ is hydrogen;

R¹⁵ is hydrogen;

10 R¹⁷ is C₁₋₆alkyl; wherein R¹⁷ may be optionally substituted on carbon by one or more substituents selected from hydroxy; or R¹⁷ is a group of formula (IC) (as depicted above) wherein:

R¹⁸ is selected from hydrogen;

R¹⁹ is selected from hydrogen;

15 R²⁰ is C₁₋₆alkyl; wherein R²⁰ may be independently optionally substituted on carbon by one or more hydroxy;

p is 1;

q is 0;

r is 0;

20 m is 0;

n is 1; and

z is 1.

One of R⁵ and R⁶ is a group of formula (IA) (as depicted above); wherein:

Z is -O- or -S(O)_b-; wherein b is 0;

25 R⁸ is hydrogen;

R⁹ is hydrogen;

R¹⁰ and R¹¹ are independently selected from hydrogen, 2-fluorophenyl or carbocyclyl;

R¹³ is a group of formula (IB) (as depicted above);

R¹⁴ is hydrogen;

30 R¹⁵ is hydrogen;

R¹⁷ is pentyl substituted by 5 hydroxy; or R¹⁷ is a group of formula (IC) (as depicted above) wherein:

R¹⁸ is selected from hydrogen;

R¹⁹ is selected from hydrogen;

R²⁰ is pentyl substituted by 5 hydroxy;

p is 1;

5 q is 0;

r is 0;

m is 0;

n is 1; and

z is 1.

10 Therefore in an further aspect of the invention, there is provided a compound of formula (I) wherein:

M¹ is -CH₂-;

M² is -CR²²R²³- and -NR²⁴-;

R²² and R²³ are independently selected from hydrogen and hydroxy;

15 R¹ and R² are C₁₋₄alkyl;

v is 0;

R⁴ and R⁷ are hydrogen;

One of R⁵ or R⁶ is selected from a group of formula (IA) (as depicted above) and the other is hydrogen or methylthio;

20 Z is -O- or -S(O)_b-; wherein b is 0;

R⁸ is hydrogen;

R⁹ is hydrogen;

R¹⁰ and R¹¹ are independently selected from hydrogen or carbocyclyl; wherein R¹⁰ and R¹¹ may be independently optionally substituted on carbon by one or more substituents

25 selected from R²⁸;

R¹³ is a group of formula (IB) (as depicted above);

R¹⁴ is hydrogen;

R¹⁵ is hydrogen;

30 R¹⁷ is C₁₋₁₀alkyl; wherein R¹⁷ may be optionally substituted on carbon by one or more substituents selected from R⁴⁷; or R¹⁷ is a group of formula (IC) (as depicted above) wherein:

R¹⁸ is selected from hydrogen;

R¹⁹ is selected from hydrogen;

R^{20} is C_{1-10} alkyl; wherein R^{20} may be independently optionally substituted on carbon by one or more R^{57} ;

p is 1;

q is 0;

5 r is 0;

m is 0;

n is 1;

z is 1; and

R^{28} , R^{47} and R^{57} are independently selected from halo and hydroxy;

10 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an further aspect of the invention, there is provided a compound of formula (I) wherein:

M^1 is $-CH_2-$;

M^2 is $-CR^{22}R^{23}-$ and $-NR^{24}-$;

15 R^{22} and R^{23} are independently selected from hydrogen and hydroxy;

One of R^1 and R^2 is ethyl and the other is butyl;

v is 0;

R^4 and R^7 are hydrogen;

One of R^5 or R^6 is selected from a group of formula (IA) (as depicted above) and the

20 other is hydrogen or methylthio;

Z is $-O-$ or $-S(O)_b-$; wherein b is 0;

R^8 is hydrogen;

R^9 is hydrogen;

R^{10} and R^{11} are independently selected from hydrogen, 2-fluorophenyl or carbocyclyl;

25 R^{13} is a group of formula (IB) (as depicted above);

R^{14} is hydrogen;

R^{15} is hydrogen;

R^{17} is pentyl substituted by 5 hydroxy; or R^{17} is a group of formula (IC) (as depicted above) wherein:

30 R^{18} is selected from hydrogen;

R^{19} is selected from hydrogen;

R^{20} is pentyl substituted by 5 hydroxy;

p is 1;

q is 0;

r is 0;

m is 0;

5 n is 1; and

z is 1;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

In another aspect of the invention, preferred compounds of the invention are any one of the examples or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a


10 prodrug thereof.

Preferred aspects of the invention are those which relate to the compound of formula (I) or a pharmaceutically acceptable salt thereof.


Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a

15 prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:

Process 1): for compounds of formula (I) wherein Z is -O-, -NR^a or -S-; reacting a compound of formula (IIa) or (IIb):




(IIa)



(IIb)

20


with a compound of formula (III):




(III)

wherein L is a displaceable group;

Process 2): reacting an acid of formula (IVa) or (IVb):




(IVa)




(IVb)

5 or an activated derivative thereof; with an amine of formula (V):




(V);

Process 3): for compounds of formula (I) wherein R^{13} is a group of formula (IB); reacting an acid of formula (VIa):




(VIa)

or (VIb):



(VIb)


with an amine of formula:



(VI)


5

Process 4): for compounds of formula (I) wherein R¹³ is a group of formula (IB) and R¹⁷ is a group of formula (IC); reacting an acid of formula (VIIIa):




(VIIIa)

10 or (VIIIb)



(VIIIb)


or an activated derivative thereof; with an amine of formula (IX):




(IX)

5

Process 5) for compounds of formula (I) wherein one of R⁵ and R⁶ are independently selected from C₁₋₆alkylthio optionally substituted on carbon by one or more R²⁵; reacting a compound of formula (Xa) or (Xb):



(Xa)



(Xb)

10

wherein L is a displaceable group; with a thiol of formula (XI):



(XI)

wherein R^m is C₁₋₆alkylthio optionally substituted on carbon by one or more R²⁵;

15 and thereafter if necessary or desirable:

i) converting a compound of the formula (I) into another compound of the formula (I);


- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug.

L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or


5 toluene-4-sulphonyloxy group.

Specific reaction conditions for the above reactions are as follows.


The bicyclic ring systems of the present invention may be assembled according to Scheme Ia (1,4-benzothiazepine) or Scheme Ib (benzothiepinines) or Scheme IC (1,2-benzothiazepines). The skilled person will appreciate to make any of the above identified
10 intermediates the value of R^4 or R^5 in the following schemes would be replaced with the appropriate group. For example, to synthesize a compound of formula (IIa) R^4 would be HX in the following schemes.



Scheme 1a



Scheme 1b



Scheme 1c

Starting materials for the above schemes are commercially available, or they are known in the literature, or they may be prepared by standard processes known in the art.

Process 1): Compounds of formula (IIa) or (IIb) may be reacted with compounds of formula (III) in the presence of a base for example an inorganic base such as sodium carbonate, or an organic base such as Hunigs base, in the presence of a suitable solvent such as acetonitrile, dichloromethane or tetrahydrofuran at a temperature in the range of 0°C to reflux, preferably at or near reflux.

Compounds of formula (III) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process 2) and *Process 3*) and *Process 4*): Acids and amines may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di-*alkyl*-pyridines such as 2,6-lutidine or 2,6-di-*tert*-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.

Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C.

Amines of formula (V), (VII) and (IX) are commercially available, or they are known in the literature, or they may be prepared by standard processes known in the art.

Process 4): Compounds of formula (Xa) and (Xb) may be reacted with thiols in the presence of base, for example an inorganic base such as sodium carbonate or an organic base such as Hunigs base, in the presence of a suitable solvent such as DMF or THF at a temperature in the range of 0°C to reflux.

Compounds of formula (Xa) and (Xb) may be prepared by any of the procedures above for the preparation of compounds of formula (I), but wherein one of R⁴ and R⁵ is L.

Compounds of formula (XI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or
5 generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such
10 procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts
15 conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be
20 necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art.

Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons,
25 1999). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group,
30 for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali

metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

As stated hereinbefore the compounds defined in the present invention possess IBAT inhibitory activity. These properties may be assessed, for example, using an *in vitro* test assay for studying the effect on bile acid uptake in IBAT-transfected cells (Smith L., Price-Jones M. J., Hugnes K. T. and Jones N. R. A.; J Biomolecular Screening, 3, 227-230) or *in vivo* by studying the effect on radiolabelled bile acid absorption in mice/rats (Lewis M. C., Brieady L. E. and Root C., J., J Lip Res 1995, 36, 1098-1105).

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in association

with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical

5 administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, will normally be administered to a warm-blooded animal at a
10 unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.02-100 mg/kg, preferably 0.02 -50 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. In another aspect of the invention the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt
15 or a prodrug thereof, will normally be administered to a warm-blooded animal at a unit dose within the range 0.001- 20 mg /kg or 0.1 - 200 mg /day, particularly 1 -20 mg/day to provide a therapeutically-effective dose. Preferably a daily dose in the range of 1-50 mg/kg, particularly 0.1-10 mg/kg is employed. In another aspect a daily dose in the range of 0.02-20 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated,
20 the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

According to a further aspect of the present invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
25 prodrug thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, are effective IBAT inhibitors, and accordingly have value in the treatment of disease states
30 associated with hyperlipidaemic conditions.

Thus according to this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use as a medicament.

According to another feature of the invention there is provided the use of a compound
5 of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound
10 of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound
15 of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of dyslipidemic conditions and disorders such as hyperlipidaemia, hypertriglyceridemia, hyperbetalipoproteinemia (high LDL), hyperprebetalipoproteinemia (high VLDL), hyperchylomicronemia, hypolipoproteinemia, hypercholesterolemia, hyperlipoproteinemia and hypoalphalipoproteinemia (low HDL) in a warm-blooded animal, such as man.

20 According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of different clinical conditions such as atherosclerosis, arteriosclerosis, arrhythmia, hyper-thrombotic conditions, vascular dysfunction, endothelial dysfunction, heart failure,
25 coronary heart diseases, cardiovascular diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, inflammation of cardiovascular tissues such as heart, valves, vasculature, arteries and veins, aneurisms, stenosis, restenosis, vascular plaques, vascular fatty streaks, leukocytes, monocytes and/or macrophage infiltration, intimal thickening, medial thinning, infectious and surgical trauma and vascular thrombosis, stroke and transient
30 ischaemic attacks in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a

prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of atherosclerosis, coronary heart diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, stroke and transient ischaemic attacks in a warm-blooded animal, such as man.

5 According to a further feature of this aspect of the invention there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

10 According to a further feature of this aspect of the invention there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

15 According to a further feature of this aspect of the invention there is provided a method of treating dyslipidemic conditions and disorders such as hyperlipidaemia, hypertriglyceridemia, hyperbetalipoproteinemia (high LDL), hyperprebetalipoproteinemia (high VLDL), hyperchylomicronemia, hypolipoproteinemia, hypercholesterolemia, hyperlipoproteinemia and hypoalphalipoproteinemia (low HDL) in a warm-blooded animal,
20 such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

 According to a further feature of this aspect of the invention there is provided a method of treating different clinical conditions such as atherosclerosis, arteriosclerosis,
25 arrhythmia, hyper-thrombotic conditions, vascular dysfunction, endothelial dysfunction, heart failure, coronary heart diseases, cardiovascular diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, inflammation of cardiovascular tissues such as heart, valves, vasculature, arteries and veins, aneurisms, stenosis, restenosis, vascular plaques, vascular fatty streaks, leukocytes, monocytes and/or macrophage infiltration, intimal
30 thickening, medial thinning, infectious and surgical trauma and vascular thrombosis, stroke and transient ischaemic attacks in need of such treatment which comprises administering to

said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further feature of this aspect of the invention there is provided a method of treating atherosclerosis, coronary heart diseases, myocardial infarction, angina
5 pectoris, peripheral vascular diseases, stroke and transient ischaemic attacks in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

There is evidence that an IBAT inhibitor might potentially be useful in the treatment
10 and/or prevention of gallstones. According to a further feature of this aspect of the invention there is provided a method of treating and / or preventing gallstones in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

15 The size of the dose required for the therapeutic or prophylactic treatment will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 0.1-50mg/kg preferably 0.1-10 mg/kg is envisaged.

The IBAT inhibitory activity defined hereinbefore may be applied as a sole therapy or
20 may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
25 prodrug thereof, as defined hereinbefore and an additional IBAT inhibitory substance as defined hereinbefore and an additional hypolipidaemic agent for the conjoint treatment of hyperlipidaemia.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in
30 association with an HMG Co-A reductase inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable HMG Co-A reductase inhibitors, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are

statins well known in the art. Particular statins are fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, dalvastatin, mevastatin and (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulphonyl)amino]pyrimidin-5-yl](3R, 5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin), or a pharmaceutically acceptable salt, 5 solvate, solvate of such a salt or a prodrug thereof. A particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is atorvastatin calcium salt. A further particular statin is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulphonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin), or a pharmaceutically acceptable salt, solvate, 10 solvate of such a salt or a prodrug thereof. A preferable particular statin is rosuvastatin calcium salt.

Therefore in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and an HMG Co-A reductase inhibitor, or a pharmaceutically 15 acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

In an additional aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof may be administered in association with an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and/or a bile acid binder 20 thereby avoiding a possible risk of excess of bile acids in colon caused by the inhibition of the ileal bile acid transport system. An excess of bile acids in the visceral contents may cause diarrhoea. Thus, the present invention also provides a treatment of a possible side effect such as diarrhoea in patients during therapy comprising the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

25 An HMG CoA-reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof will by its action decrease the endogenous cholesterol available for the bile acid synthesis and have an additive effect in combination with the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof on lipid lowering.

30 Suitable bile acid binders for such a combination therapy are resins, such as cholestyramine and cholestipol. One advantage is that the dose of bile acid binder might be kept lower than the therapeutic dose for treatment of cholesterolaemia in single treatment

comprising solely a bile acid binder. By a low dose of bile acid binder any possible side effects caused by poor tolerance of the patient to the therapeutic dose could also be avoided.

Therefore in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a
5 salt or a prodrug thereof and a bile acid binder.

Therefore in an additional feature of the invention, there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
10 prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such
15 treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with a bile acid binder.

Therefore in an additional feature of the invention, there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such
20 treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in simultaneous, sequential or separate
25 administration with a bile acid binder.

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
30 prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a bile acid binder.

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in simultaneous, sequential or separate administration with a bile acid binder.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate

of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate
5 of such a salt or a prodrug thereof, and a bile acid binder.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a bile
10 acid binder.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- 15 b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- 20 a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- b) a bile acid binder; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit
25 comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form;
- 30 c) a bile acid binder; in a third unit dosage form; and
- d) container means for containing said first, second and third dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) a bile acid binder, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) a bile acid binder; in a third unit dosage form; and
- d) container means for containing said first, second and third dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a

prodrug thereof, and a bile acid binder, in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
5 prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder, in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound
10 of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound
15 of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, a bile acid binder, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
20 prodrug thereof, an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination
25 treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
30 prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the
5 simultaneous, sequential or separate administration of an effective amount of a bile acid binder, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula
10 (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable excipient, with the
15 simultaneous, sequential or separate administration of an effective amount of a bile acid binder, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound
20 of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration one or more of the following agents selected from Group X:

- a CETP (cholesteryl ester transfer protein) inhibitor, for example those referenced and
25 described in WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference;
- a cholesterol absorption antagonist for example azetidinones such as SCH 58235 and those described in US 5,767,115 which are incorporated herein by reference;
- a MTP (microsomal transfer protein) inhibitor for example those described in Science,
30 282, 751-54, 1998 which are incorporated herein by reference;
- a fibric acid derivative; for example clofibrate, gemfibrozil, fenofibrate, ciprofibrate and bezafibrate;

- a nicotinic acid derivative, for example, nicotinic acid (niacin), acipimox and niceritrol;
- a phytosterol compound for example stanols;
- probucol;
- 5 ➤ an anti-obesity compound for example orlistat (EP 129,748) and sibutramine (GB 2,184,122 and US 4,929,629);
- an antihypertensive compound for example an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, an andrenergic blocker, an alpha andrenergic blocker, a beta andrenergic blocker, a mixed alpha/beta andrenergic
- 10 blocker, an andrenergic stimulant, calcium channel blocker, a diuretic or a vasodilator;
- insulin;
- sulphonylureas including glibenclamide, tolbutamide;
- metformin; and/or
- acarbose;
- 15 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Particular ACE inhibitors or pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof, including active metabolites, which can be used in

20 combination with a compound of formula (I) include but are not limited to, the following compounds: alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril

25 sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphan-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril,

30 spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril and zofenoprilat. Preferred ACE inhibitors for use in the present invention are ramipril, ramiprilat, lisinopril, enalapril and

enalaprilat. More preferred ACE inhibitors for uses in the present invention are ramipril and ramiprilat.

Preferred angiotensin II antagonists, pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof for use in combination with a compound of formula (I) include, but are not limited to, compounds: candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan. Particularly preferred angiotensin II antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil.

Therefore, in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a compound from Group X or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidaemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with a PPAR alpha and/or gamma agonist, or pharmaceutically acceptable salts,

solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, WO 99/62871, WO 98/57941, WO 01/40170, J Med Chem, 1996, 39, 665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000, 43, 527 which are all incorporated herein by reference. Particularly a PPAR alpha and/or gamma agonist refers to WY-14643, clofibrate, fenofibrate, bezafibrate, GW 9578, troglitazone, pioglitazone, rosiglitazone, eglitazone, proglitazone, BRL-49634, KRP-297, JTT-501, SB 213068, GW 1929, GW 7845, GW 0207, L-796449, L-165041 and GW 2433. Particularly a PPAR alpha and/or gamma agonist refers to (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl}ethoxy)phenyl] propanoic acid and pharmaceutically acceptable salts thereof. Additional suitable PPAR alpha and/or gamma agonists are NN622/Ragaglitazar and BMS 298585.

Therefore in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- b) a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt,

solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

In addition to their use in therapeutic medicine, the compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of IBAT in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

Many of the intermediates described herein are novel and are thus provided as a further feature of the invention. For example compounds of formula (IVa), (IVb), (VIa), (VIb), (VIIIa) and (VIIIb) show IBAT inhibitory activity when tested in the above referenced *in vitro* test assay.

Thus in a further feature of the invention, there is provided a compound of formula (IVa), (IVb), (VIa), (VIb), (VIIIa) or (VIIIb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; with the proviso that when R¹¹ and R¹² are selected from carbocyclyl and / or heterocyclyl, said carbocyclyl and heterocyclyl are not totally unsaturated.

Therefore according to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (IVa), (IVb), (VIa), (VIb), (VIIIa) or (VIIIb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier; with the proviso that when R¹¹ and R¹² are selected from carbocyclyl and / or heterocyclyl, said carbocyclyl and heterocyclyl are not totally unsaturated.

According to an additional aspect of the present invention there is provided a

compound of the formula (IVa), (IVb), (VIa), (VIb), (VIIIa) or (VIIIb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man; with the proviso that when R¹¹ and R¹² are selected from carbocyclyl and / or heterocyclyl, said carbocyclyl and heterocyclyl are not totally unsaturated.

Thus according to this aspect of the invention there is provided a compound of the formula (IVa), (IVb), (VIa), (VIb), (VIIIa) or (VIIIb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use as a medicament; with the proviso that when R¹¹ and R¹² are selected from carbocyclyl and / or heterocyclyl, said carbocyclyl and heterocyclyl are not totally unsaturated.

According to another feature of the invention there is provided the use of a compound of the formula (IVa), (IVb), (VIa), (VIb), (VIIIa) or (VIIIb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof as defined hereinbefore in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man; with the proviso that when R¹¹ and R¹² are selected from carbocyclyl and / or heterocyclyl, said carbocyclyl and heterocyclyl are not totally unsaturated.

According to another feature of the invention there is provided the use of a compound of the formula (IVa), (IVb), (VIa), (VIb), (VIIIa) or (VIIIb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof as defined hereinbefore in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man; with the proviso that when R¹¹ and R¹² are selected from carbocyclyl and / or heterocyclyl, said carbocyclyl and heterocyclyl are not totally unsaturated.

According to a further feature of this aspect of the invention there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (IVa), (IVb), (VIa), (VIb), (VIIIa) or (VIIIb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; with the proviso that when R¹¹ and R¹² are selected from carbocyclyl and / or heterocyclyl, said carbocyclyl and heterocyclyl are not totally unsaturated.

According to a further feature of this aspect of the invention there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a

compound of formula (IVa), (IVb), (VIa), (VIb), (VIIIa) or (VIIIb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; with the proviso that when R^{11} and R^{12} are selected from carbocyclyl and / or heterocyclyl, said carbocyclyl and heterocyclyl are not totally unsaturated.

- 5 In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

Examples

- The invention will now be illustrated in the following non limiting examples, in which
- 10 standard techniques known to the skilled chemist and techniques analogous to those described in these examples may be used where appropriate, and in which, unless otherwise stated:
- (i) evaporations were carried out by rotary evaporation in vacuo and work up procedures were carried out after removal of residual solids such as drying agents by filtration;
 - (ii) all reactions were carried out under an inert atmosphere at ambient temperature, typically
 - 15 in the range 18-25°C, with solvents of HPLC grade under anhydrous conditions, unless otherwise stated;
 - (iii) column chromatography (by the flash procedure) was performed on Silica gel 40-63 μm (Merck);
 - (iv) yields are given for illustration only and are not necessarily the maximum attainable;
 - 20 (v) the structures of the end products of the formula (I) were generally confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; magnetic resonance chemical shift values were measured in deuterated CD_3OD (unless otherwise stated) on the delta scale (ppm downfield from tetramethylsilane); proton data is quoted unless otherwise stated; spectra were recorded on a Varian Mercury-300 MHz, Varian Unity
 - 25 plus-400 MHz, Varian Unity plus-600 MHz or on Varian Inova-500 MHz spectrometer; and peak multiplicities are shown as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; tt, triple triplet; q, quartet; tq, triple quartet; m, multiplet; br, broad; LCMS were recorded on a Waters ZMD, LC column xTerra MS C_8 (Waters), detection with a HP 1100 MS-detector diode array equipped; mass spectra (MS) (loop) were recorded on VG Platform II (Fisons
 - 30 Instruments) with a HP-1100 MS-detector diode array equipped; unless otherwise stated the mass ion quoted is (MH^+) ;

(vi) unless further details are specified in the text, analytical high performance liquid chromatography (HPLC) was performed on Prep LC 2000 (Waters), Kromasil C₈, 7 μ m, (Akzo Nobel); MeCN and de-ionised water 100 mM ammonium acetate as mobile phases, with suitable composition;

5 (vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), HPLC, infra-red (IR), MS or NMR analysis;

(viii) where solutions were dried sodium sulphate was the drying agent;

(ix) where an "ISOLUTE" column is referred to, this means a column containing 2g of silica, the silica being contained in a 6ml disposable syringe and supported by a porous disc of 54Å

10 pore size, obtained from International Sorbent Technology under the name "ISOLUTE";

"ISOLUTE" is a registered trade mark;

(x) the following abbreviations may be used hereinbefore or hereinafter:-

DCM dichloromethane;

DMF N,N-dimethylformamide;

15 TFA trifluoroacetic acid;

TBTU o-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate;

EtOAc ethyl acetate; and

MeCN acetonitrile.

20 **Example 1**

(+/-)-trans-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine

(+/-)-trans-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-8-(carboxymethoxy)-2,3,4,5-

25 tetrahydro-1,4-benzothiazepine (Method 2; 20 mg, 0.043 mmol), (R)- α -[N'-(2-(S)-3-(R)-4-

(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzylamine (Method 10; 19 mg, 0.064

mmol) and N- methylmorpholine (27 mg, 0.26 mg) were dissolved in DMF and stirred at

room temperature. TBTU (19 mg, 0.059) mmol was added and the reaction mixture was

stirred for 2 hours. LC-MS indicated no unreacted starting material. A small amount of water

30 and acetonitrile was added and the the product was purified by preparative HPLC on a C8

column using a gradient from 5% to 100% MeCN in 0.1M ammonium acetate buffer as

mobile phase. Lyophilisation gave 27 mg of the title compound. NMR (400 MHz, CD₃OD):

0.81 (t, 3H), 0.89 (t, 3H), 1.11-1.35 (m, 4H), 1.4-1.5 (m, 1H), 1.52-1.63 (m, 1H), 1.74-1.85 (m, 1H), 1.94 (s, 3H), 2.27-2.28 (m, 1H), 3.11-3.25 (m, 2H), 3.46-3.53 (m, 2H), 3.53-3.75 (m, 5H), 3.78-3.84 (m, 1H), 4.63-4.66 (m, 1H), 5.51 (s, 1H), 6.0 (s, 1H), 6.59-6.64 (m, 1H), 6.95-7.01 (m, 1H), 7.27-7.35 (m, 4H), 7.35-7.41 (m, 6H), 7.66 (t, 1H).

5

Example 2

(+/-)-trans-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine

- 10 3,5-*trans*-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine (Method 6; 2mg, 3 μ mol) was dissolved in 0.5ml DMF. (D)-Glucamine (2mg, 11 μ mol), N-methyl morpholine (ca 1 μ l, 9 μ mol) and TBTU (1.1mg, 4 μ mol) were added and the solution was stirred for 3hours. The reaction was completed according to LC/MS-analysis.
- 15 The product was purified by preparative HPLC on a C8 column using a gradient from 5% to 100% MeCN in 0.1M ammonium acetate buffer as mobile phase. The product fraction was lyophilised to yield 2.4mg (95%). LC/Micromass Q TOF micro MS analysis showed four peaks corresponding to four isomers of the product with a total purity of 96%; m/z=831.328.

20 **Example 3**

1,1-Dioxo-3-ethyl-3-butyl-4-hydroxy-5-phenyl-7-(N-{ α -[N-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-2-fluorobenzyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine

- 1,1-Dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-{N-[α -(carboxy)-2-fluorobenzyl]carbamoylmethylthio}-2,3,4,5-tetrahydrobenzothiepine (Method 3; 28 mg, 0.046 mmol) and D-glucamine (10 mg, 0.055 mmol) were added to DMF (2.0 ml) and 2,6-lutidine (0.02 ml, 0.14 mmol) was added. When everything had dissolved TBTU (20 mg, 0.060 mmol) was added and the reaction mixture was stirred at ambient temperature overnight. More D-glucamine (10 mg, 0.055 mmol) and TBTU (20 mg, 0.060 mmol) were added and the reaction
- 30 mixture was stirred for another 3 hours. The reaction mixture was purified by preparative HPLC using MeCN/ammonium acetate buffer (gradient 50:50 to 100:0) to give the title compound (9.0 mg, 25 %). NMR (400 MHz, DMSO-d₆): 0.73 (t, 3 H), 0.83 (t, 3 H), 1.00 (m,

1 H), 1.20-1.45 (m, 5 H), 1.59 (m, 1 H), 2.01 (m, 1 H), 3.10 (m, 2 H), 3.94 (s, 1 H), 5.22 (d, 1 H), 5.60 (d, 1 H), 6.41 (dd, 1 H), 7.13 (m, 3 H), 7.25-7.43 (m, 8 H), 7.74 (dd, 1 H), 8.08 (br s, 1 H), 8.89 (br s, 1 H).

5 Example 4

1,1-Dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(N-{1-[N-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-1-(cyclohexyl)methyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine

1,1-Dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(N-[1-(carboxy)-1-(cyclohexyl)methyl] carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine (Method 5; 4 mg, 0.0066 mmol), D-glucamine (2 mg, 0.0088 mmol) and N-methylmorpholine (4 mg, 0.035 mmol) were dissolved in DMF and stirred at room temperature for 10 min. TBTU (0.003 mg, 0.0087 mmol) and the reaction mixture was stirred over night. A small amount of water and acetonitrile was added and the product was purified by preparative HPLC on a C8 column using a gradient from 5% to 100% MeCN in 0.1 %M ammonium acetate buffer as mobile phase. Lyophilization gave (1.7 mg 33.4%) of the title compound. LC/MicromassQ TOF micro MS analysis showed two peaks corresponding to two isomers of the product with a total purity of 96%; m/z=765.343

20 Preparation of Starting Materials

The starting materials for the Examples above are either commercially available or are readily prepared by standard Methods from known materials. For example, the following reactions are an illustration, but not a limitation, of some of the starting materials used in the above reactions.

25

Method 1

(+/-)-trans-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-8-(t-butoxycarbonylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine

A mixture of (+/-)-trans-1,1-dioxo-3-butyl-3-ethyl-5-phenyl-8-hydroxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (prepared according to WO/9605188; 52 mg, 0.14 mmol), t-butyl bromoacetate (32 mg, 0.16 mmol), potassium carbonate (76 mg, 0.55 mmol) and cesium carbonate (12 mg, 0.036 mmol) in acetonitrile was stirred at 50 C for 2 hours. The solvent was removed at reduced pressure and the crude product was purified by chromatography. The

eluent was initially DCM and thereafter switched to EtOAc:DCM, 1:10. 0.055 g of the desired product was obtained.

Method 2

5 (+/-)-trans-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-8-(carboxymethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine

(+/-)-trans-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-8-(*t*-butoxycarbonylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine (Method 1; 58 mg, 0.12 mmol) was dissolved in formic acid and stirred for 20 hours at ambient temperature and then for 4 hours at 45°C. The formic acid
10 was removed at reduced pressure. Toluene was added to the residue and the toluene and remaining formic acid were removed at reduced pressure to give the desired product (50 mg, 0.12 mmol).

Method 3

15 1,1-Dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-{*N*-[α -(carboxy)-2-fluorobenzyl] carbamoylmethylthio}-2,3,4,5-tetrahydrobenzothiepine

1,1-Dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(carboxymethylthio)-2,3,4,5-tetrahydrobenzothiepine (Method 4; 59 mg, 0.13 mmol) and methyl amino(2-fluorophenyl)acetate hydrochloride (40 mg, 0.18 mmol) were added to DCM (3.0 ml) and 2,6-
20 lutidine (0.04 ml, 0.38 mmol) was added. The reaction mixture was stirred at ambient temperature for 5 min and TBTU (58 mg, 0.18 mmol) was added. After stirring at ambient temperature for 3 hours the reaction mixture was diluted with DCM (5 ml) and was washed with HCl (aq., 1 M, 5 ml). The solvent was evaporated and the residue was dissolved in THF (2.0 ml) and water (1.0 ml) and NaOH (aq., 1 M, 0.30 mmol) was added. After stirring at
25 ambient temperature for 2 h the reaction mixture was quenched with HCl (aq., 1 M), diluted with water (10 ml) and extracted with DCM (3 x 5 ml). The combined organic layers were purified with preparative HPLC MeCN/ ammonium acetate buffer 40:60 to give the title compound (70 mg, 89 %). NMR (400 MHz, DMSO- d_6): 0.74 (t, 3 H), 0.84 (t, 3 H), 1.00 (m, 1 H), 1.18-1.46 (m, 5 H), 1.60 (m, 1 H), 2.02 (m, 1 H), 3.11 (m, 2 H), 3.69 (m, 2 H), 3.94 (s, 1
30 H), 5.04 (t, 1 H), 5.23 (d, 1 H), 6.44 (d, 1 H), 6.94-7.44 (m, 11 H), 7.70 (t, 1 H), 8.40 (m, 1 H).

Method 4**1,1-Dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(carboxymethylthio)-2,3,4,5-tetrahydrobenzothiepine****1,1-Dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-fluoro-2,3,4,5-**

- 5 tetrahydrobenzothiepine (prepared according to WO 98/40375; 300 mg, 0.77 mmol) was dissolved in DMF (3 ml) and caesium carbonate (540 mg, 1.66 mmol) was added followed by ethyl thioglycolate (0.17 ml, 1.54 mmol) and the reaction mixture was subjected to microwave irradiation in a Smith Synthesiser at 100°C for 5 min. The reaction mixture was added to water (25 ml), extracted with DCM (5 x 5 ml) and concentrated. The crude ethyl ester was
- 10 dissolved in THF (4 ml) and water (2 ml) and NaOH (1 M, 4 ml) was added. The reaction mixture was stirred at ambient temperature for 6 hours, quenched with HCl (1 M), diluted with water (25 ml) and extracted with DCM (4 x 5 ml). The combined organic layers were purified with preparative HPLC using MeCN/ammonium acetate buffer as the eluent (50:50) to give the title compound (172 mg, 48 %). NMR (400 MHz, DMSO-d₆): 0.74 (t, 3H), 0.84 (t,
- 15 3H), 1.01 (m, 1H), 1.18-1.46 (m, 5H), 1.60 (m, 1H), 2.02 (m, 1H), 3.07/3.12 (ABq, 2H), 3.33/3.39 (ABq, 2H), 3.95 (s, 1H), 5.23 (s, 1H), 6.38 (d, 1H), 7.19 (dd, 1H), 7.34 (m, 1H), 7.42 (m, 4H), 7.73 (d, 1H).

Method 5

- 20 **1,1-Dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-{N-[1-(carboxy)-1-(cyclohexyl)methyl]carbamoylmethylthio}-2,3,4,5-tetrahydrobenzothiepine**

The title compound was synthesised according to the same procedure as Method 3 but using methyl amino(cyclohexyl)acetate hydrochloride as starting material. NMR (400 MHz, DMSO-d₆): 0.74 (t, 3 H), 0.84 (t, 3 H), 0.92-1.10 (m, 6 H), 1.20-1.66 (m, 12 H), 2.01 (m, 1

25 H), 3.07/3.13 (ABq, 2 H), 3.60-3.75 (m, 3 H), 3.95 (m, 2 H), 5.24 (s, 1 H), 6.44 (m, 1 H), 7.33 (m, 1 H), 7.41 (m, 4 H), 7.75 (d, 1 H), 7.98 (t, 1 H).

Method 6

3,5-*trans*-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine

- 5 3,5-*trans*-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(carboxymethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine (Method 7; 50 mg, 0.105 mmol) was dissolved in DCM (2 ml). 2,6-Lutidine (0.025 ml, 0.215 mmol), TBTU (45 mg, 0.140 mmol) and (R)- α -[*N*-(*t*-butoxycarbonylmethyl)carbamoyl]benzylamine (Method 4; 43 mg, 0.163 mmol) were added successively. The mixture was stirred for 2 hours at ambient temperature. The solution
- 10 was concentrated and the intermediate ester was purified by chromatography on silica using DCM/EtOAc (9/1) as eluent. The solvent was evaporated to yield 45 mg (60%). *M/z*: 724. The ester was dissolved in 3 ml DCM and hydrolysed by addition of TFA (1 ml). After 2 hours the mixture was concentrated and purified using preparative HPLC. A gradient of MeCN from 40% to 60% in 0.1 M ammonium acetate buffer was used as eluent.
- 15 Lyophilisation yielded 33 mg (80%). NMR (400 MHz): 0.75-0.85 (m, 3H), 0.85-0.95 (m, 3H), 1.1-1.65 (m, 6H), 1.75-1.9 (m, 1H), 2.0 (s, 3H), 2.2-2.4 (m, 1H), 3.1-3.55 (m, 2H), 3.85 (ABq, 2H), 4.6-4.8 (m, 2H), 5.6 (s, 1H), 5.98-6.03 (m, 1H), 6.4 (s, 1H), 7.25-7.56 (m, 11H); *m/z*: 668.

20 Method 7

3,5-*trans*-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(carboxymethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine

- The title compound was prepared from 3,5-*trans*-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-hydroxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (Method 8; 153 mg, 0.36
- 25 mmol), ethylbromoacetate (75 mg, 0.45 mmol), sodium carbonate (162 mg, 1.52 mmol) and tetrabutylammonium bromide (12 mg, 0.037 mmol) in acetonitrile (10 ml). The intermediate ethyl ester was extracted between diluted HCl and DCM. The DCM phase was washed with brine, dried with Na₂SO₄ and concentrated. *M/z* 506. The crude product was dissolved in THF/H₂O (3/1; 4 ml) and LiOH (22 mg, 0.91 mmol) was added. The mixture was stirred for
- 30 2h and the solvent was removed under reduced pressure. The crude product was purified using preparative HPLC. A gradient from 40% to 60% MeCN in 0.1 M ammonium acetate buffer was used as eluent. The MeCN was removed under reduced pressure and the remaining

aqueous solution was acidified using 5% HCl and was then extracted with DCM. The DCM layer was dried with Na₂SO₄ and concentrated. The crude product was co-evaporated with diethyl ether. The obtained crystals were filtered off and dried. Mass: 158 mg (91%). NMR 0.75 (t, 3H), 0.9 (t, 3H), 1.1-1.7 (m, 6H), 1.7-1.9 (m, 1H), 2.0 (s, 3H), 2.2-2.4 (m, 1H), 3.3 (dd, 5 2H), 4.75 (s, 2H), 6.0 (s, 1H), 6.4 (s, 1H), 7.3-7.5 (m, 6H); m/z: 478.

Method 8

3,5-trans-1,1-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-hydroxy-2,3,4,5-tetrahydro-1,4-benzothiazepine

10 (+/-)-trans-7-Bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-8-methoxy-5-phenyl-1,4-benzothiazepine 1,1-dioxide (prepared according to WO 96/05188; 300 mg, 0.64 mmol) was dissolved in 5 ml DMF under N₂(g)-atmosphere. Sodium thiomethylate (150 mg, 2.14 mmol) was added and the mixture was heated to 110°C for 2h. The solvent was removed under reduced pressure and the residue was extracted between 5% HCl and EtOAc. The organic
15 phase was washed with brine, dried with Na₂SO₄ and concentrated. The product was purified using preparative HPLC. A gradient from 40% to 100% of MeCN in 0.1 M ammonium acetate buffer was used as eluent. Lyophilisation yielded 153 mg, 57%. M/z: 420.

Method 9

20 (N-{(R)-α-[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-Pentahydroxyhexyl)carbamoyl]benzyl} carbamoyl)oxymethylphenyl

(2R)-{[(Benzyloxy)carbonyl]amino}(phenyl)acetic acid (2.07g, 7.26 mmol), (2R,3R,4R,5S)-6-aminoheptane-1,2,3,4,5-pentol (1.44g, 7.9 mmol) and 2,6-dimethylpyridine (0.933g, 8.7 mmol) were dissolved in DMF (30 ml). TBTU (3.80g, 8.7 mmol) was added and
25 the mixture was stirred for 1.5 hour. (2R,3R,4R,5S)-6-aminoheptane-1,2,3,4,5-pentol (0.21g, 0.2 mmol) was added and the mixture was stirred for 1 hour. The solvent was evaporated under reduced pressure. The mixture was dissolved in isopropanol (35 ml), heated to 80-100°C. The mixture was then allowed to reach room temperature. The formed crystals was filtered off and washed with isopropanol (2 x 20 ml) and two times with diethyl ether (2 x 25
30 ml). The crystals was recrystallized using isopropanol (100 ml) heated to reflux. The mixture was then allowed to reach room temperature. The crystals was filtered off and washed with small portions of isopropanol (totally 170 ml) and with diethyl ether (2 x 50 ml) to yield

2.517g (77%) of the product. NMR (600 MHz, CD₃OD): 3.15-3.23 (m, 1H), 3.48 (dd, 1H), 3.53-3.68 (m, 4H), 3.71 (dd, 1H), 3.77-3.83 (m, 1H), 5.08 (s, 2H), 5.20 (s, 1H), 7.24-7.36 (m, 8H), 7.39 (brd, 2H).

5 Method 10

(R)- α -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-Pentahydroxyhexyl)carbamoyl]benzylamine


(N-{(R)- α -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-Pentahydroxyhexyl)carbamoyl]

benzyl}carbamoyl)oxymethylphenyl (Method 9; 2.46g, 5.49 mmol), palladium on activated carbon (5%, 0.535g) and water (1.5 ml) were dissolved in ethanol (80 ml). The mixture was

10 treated under H₂-atmosphere overnight. The mixture was filtered through hyflo and the solvent was evaporated under reduced pressure to yield 1.543g (89.5%) of the title compound. NMR (400 MHz, CD₃OD): 3.23 (dd, 1H), 3.49 (dd, 1H), 3.56-3.62 (m, 2H), 3.63-3.70 (m, 2H), 3.73 (dd, 1H), 3.79-3.84 (m, 1H), 4.48 (s, 1H), 7.25-7.37 (m, 3H), 7.41 (brd, 2H).

Claims

1. A compound of formula (I):



(I)

wherein

M^1 is $-CH_2-$ or $-NR^{21}-$;

M^2 is $-CR^{22}R^{23}-$ or $-NR^{24}-$; provided that if M^1 is $-NR^{21}-$, M^2 is $-CR^{22}R^{23}-$;


One of R^1 and R^2 are selected from hydrogen, C_{1-6} alkyl or C_{2-6} alkenyl and the other is selected from C_{1-6} alkyl or C_{2-6} alkenyl;

R^3 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, $N-(C_{1-6}alkyl)amino$, $N,N-(C_{1-6}alkyl)_2amino$, $C_{1-6}alkanoylamino$, $N-(C_{1-6}alkyl)carbamoyl$, $N,N-(C_{1-6}alkyl)_2carbamoyl$, $C_{1-6}alkylS(O)_a$ wherein a is 0 to 2, $C_{1-6}alkoxycarbonyl$,

$N-(C_{1-6}alkyl)sulphamoyl$ and $N,N-(C_{1-6}alkyl)_2sulphamoyl$;

v is 0-5;

one of R^5 and R^6 is a group of formula (IA):



(IA)

R^4 and R^7 and the other of R^5 and R^6 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, $N-(C_{1-4}alkyl)amino$, $N,N-(C_{1-4}alkyl)_2amino$, $C_{1-4}alkanoylamino$, $N-(C_{1-4}alkyl)carbamoyl$,

N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, *N*-(C₁₋₄alkyl)sulphamoyl and *N,N*-(C₁₋₄alkyl)₂sulphamoyl; wherein R⁴ and R⁷ and the other of R⁵ and R⁶ may be optionally substituted on carbon by one or more R²⁵;

Z is -O-, -N(R^a)-, -S(O)_b- or -CH(R^a)-; wherein R^a is hydrogen or C₁₋₆alkyl and b is 0-
5 2;

R⁸ is hydrogen, C₁₋₄alkyl, carbocyclyl or heterocyclyl; wherein R⁸ may be optionally substituted on carbon by one or more substituents selected from R²⁶; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R²⁷;


10 R⁹ is hydrogen or C₁₋₄alkyl;

R¹⁰ and R¹¹ are independently selected from hydrogen, C₁₋₄alkyl, carbocyclyl or heterocyclyl; or R¹⁰ and R¹¹ together form C₂₋₆alkylene; wherein R¹⁰ and R¹¹ or R¹⁰ and R¹¹ together may be independently optionally substituted on carbon by one or more substituents selected from R²⁸; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen

15 may be optionally substituted by one or more R²⁹;

R¹² is hydrogen, C₁₋₄alkyl, carbocyclyl or heterocyclyl; wherein R¹² may be optionally substituted on carbon by one or more substituents selected from R³⁰; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by one or more R³¹;

20 R¹³ is hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₁₋₁₀alkoxy, C₁₋₁₀alkoxycarbonyl, C₁₋₁₀alkanoyl, C₁₋₁₀alkanoyloxy, *N*-(C₁₋₁₀alkyl)amino, *N,N*-(C₁₋₁₀alkyl)₂amino, *N,N,N*-(C₁₋₁₀alkyl)₃ammonio, C₁₋₁₀alkanoylamino, *N*-(C₁₋₁₀alkyl)carbamoyl, *N,N*-(C₁₋₁₀alkyl)₂carbamoyl, C₁₋₁₀alkylS(O)_a wherein a is 0 to 2,
25 *N*-(C₁₋₁₀alkyl)sulphamoyl, *N,N*-(C₁₋₁₀alkyl)₂sulphamoyl, *N*-(C₁₋₁₀alkyl)sulphamoylamino, *N,N*-(C₁₋₁₀alkyl)₂sulphamoylamino, C₁₋₁₀alkoxycarbonylamino, carbocyclyl, carbocyclylC₁₋₁₀alkyl, heterocyclic group, heterocyclylC₁₋₁₀alkyl, carbocyclyl-(C₁₋₁₀alkylene)_e-R³²-(C₁₋₁₀alkylene)_f or heterocyclyl-(C₁₋₁₀alkylene)_g-R³³-(C₁₋₁₀alkylene)_h-; wherein R¹³ may be optionally substituted
30 on carbon by one or more substituents selected from R³⁶; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R³⁷; or R¹³ is a group of formula (IB):



(IB)

wherein:

X is $-\text{N}(\text{R}^{38})-$, $-\text{N}(\text{R}^{38})\text{C}(\text{O})-$, $-\text{O}-$, and $-\text{S}(\text{O})_a-$; wherein a is 0-2 and R^{38} is hydrogen or

5 C_{1-4} alkyl;


R^{14} is hydrogen or C_{1-4} alkyl;

R^{15} and R^{16} are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino,

10 C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkyl $\text{S}(\text{O})_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl) $_2$ sulphamoyl, carbocyclyl or heterocyclic group; wherein R^{15} and R^{16} may be independently optionally substituted on carbon by one or more substituents selected from R^{41} ; and wherein if said heterocyclyl contains an $-\text{NH}-$ group, that nitrogen may be optionally substituted by a group
15 selected from R^{42} ;

R^{17} is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkanoyl, C_{1-10} alkanoyloxy, N -(C_{1-10} alkyl)amino, N,N -(C_{1-10} alkyl) $_2$ amino, C_{1-10} alkanoylamino, N -(C_{1-10} alkyl)carbamoyl, C_{1-10} alkoxycarbonyl,

20 N,N -(C_{1-10} alkyl) $_2$ carbamoyl, C_{1-10} alkyl $\text{S}(\text{O})_a$ wherein a is 0 to 2, N -(C_{1-10} alkyl)sulphamoyl, N,N -(C_{1-10} alkyl) $_2$ sulphamoyl, N -(C_{1-10} alkyl)sulphamoylamino, N,N -(C_{1-10} alkyl) $_2$ sulphamoylamino, carbocyclyl, carbocyclyl C_{1-10} alkyl, heterocyclic group, heterocyclyl C_{1-10} alkyl, carbocyclyl-(C_{1-10} alkylene) $_e$ - R^{43} -(C_{1-10} alkylene) $_f$ or heterocyclyl-(C_{1-10} alkylene) $_g$ - R^{44} -(C_{1-10} alkylene) $_h$; wherein R^{17} may be optionally substituted
25 on carbon by one or more substituents selected from R^{47} ; and wherein if said heterocyclyl contains an $-\text{NH}-$ group, that nitrogen may be optionally substituted by a group selected from R^{48} ; or R^{17} is a group of formula (IC):



(IC)

wherein:

R^{18} is selected from hydrogen or C_{1-4} alkyl;

- 5 R^{19} is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl) $_2$ sulphamoyl, carbocyclyl or
10 heterocyclic group; where R^{19} may be independently optionally substituted on carbon by one or more substituents selected from R^{51} ; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{52} ;

- R^{20} is selected from halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkoxycarbonyl, C_{1-10} alkanoyl, C_{1-10} alkanoyloxy, N -(C_{1-10} alkyl)amino, N,N -(C_{1-10} alkyl) $_2$ amino, N,N,N -(C_{1-10} alkyl) $_3$ ammonio, C_{1-10} alkanoylamino, N -(C_{1-10} alkyl)carbamoyl, N,N -(C_{1-10} alkyl) $_2$ carbamoyl, C_{1-10} alkylS(O) $_a$ wherein a is 0 to 2, N -(C_{1-10} alkyl)sulphamoyl, N,N -(C_{1-10} alkyl) $_2$ sulphamoyl, N -(C_{1-10} alkyl)sulphamoylamino, N,N -(C_{1-10} alkyl) $_2$ sulphamoylamino, C_{1-10} alkoxycarbonylamino, carbocyclyl,
15 carbocyclyl C_{1-10} alkyl, heterocyclic group, heterocyclyl C_{1-10} alkyl, carbocyclyl-(C_{1-10} alkylene) $_e$ - R^{53} -(C_{1-10} alkylene) $_f$ or heterocyclyl-(C_{1-10} alkylene) $_g$ - R^{54} -(C_{1-10} alkylene) $_h$; wherein R^{20} may be independently optionally substituted on carbon by one or more R^{57} ; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{58} ;

- 25 p is 1-3; wherein the values of R^{15} may be the same or different;

q is 0-1;

r is 0-3; wherein the values of R^{16} may be the same or different;

m is 0-2; wherein the values of R^{12} may be the same or different;

n is 1-2; wherein the values of R^8 may be the same or different;

- 30 z is 0-3; wherein the values of R^{19} may be the same or different;

R^{21} is selected from hydrogen or C_{1-6} alkyl;

R^{22} and R^{23} are independently selected from hydrogen, hydroxy, amino, mercapto, C_{1-6} alkyl, C_{1-6} alkoxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkylS(O)_a wherein a is 0 to 2;

5 R^{24} is selected from hydrogen, hydroxy, C_{1-6} alkyl, C_{1-4} alkoxy and C_{1-6} alkanoyloxy;

R^{25} is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl,

10 N -(C_{1-4} alkyl)sulphamoyl and N,N -(C_{1-4} alkyl)₂sulphamoyl; wherein R^{25} , may be independently optionally substituted on carbon by one or more R^{67} ;

R^{26} , R^{28} , R^{30} , R^{36} , R^{41} , R^{47} , R^{51} and R^{57} are independently selected from halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{1-10} alkanoyl, C_{1-10} alkanoyloxy, C_{1-10} alkoxycarbonyl,

15 N -(C_{1-10} alkyl)amino, N,N -(C_{1-10} alkyl)₂amino, N,N,N -(C_{1-10} alkyl)₃ammonio, C_{1-10} alkanoylamino, N -(C_{1-10} alkyl)carbamoyl, N,N -(C_{1-10} alkyl)₂carbamoyl, C_{1-10} alkylS(O)_a wherein a is 0 to 2, N -(C_{1-10} alkyl)sulphamoyl, N,N -(C_{1-10} alkyl)₂sulphamoyl, N -(C_{1-10} alkyl)sulphamoylamino, N,N -(C_{1-10} alkyl)₂sulphamoylamino, C_{1-10} alkoxycarbonylamino, carbocyclyl, carbocyclyl C_{1-10} alkyl, heterocyclic group,

20 heterocyclyl C_{1-10} alkyl, carbocyclyl-(C_{1-10} alkylene)_e- R^{59} -(C_{1-10} alkylene)_f or heterocyclyl-(C_{1-10} alkylene)_g- R^{60} -(C_{1-10} alkylene)_h; wherein R^{26} , R^{28} , R^{30} , R^{36} , R^{41} , R^{47} , R^{51} and R^{57} may be independently optionally substituted on carbon by one or more R^{63} ; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{64} ;

25 R^{27} , R^{29} , R^{31} , R^{37} , R^{42} , R^{48} , R^{52} , R^{58} and R^{64} are independently selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, sulphamoyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, benzyl, phenethyl, benzoyl, phenylsulphonyl and phenyl;

R^{32} , R^{33} , R^{43} , R^{44} , R^{53} , R^{54} , R^{59} and R^{60} are independently selected from -O-, - NR^{65} -,
30 -S(O)_x-, - $NR^{65}C(O)NR^{66}$ -, - $NR^{65}C(S)NR^{66}$ -, -OC(O)N=C-, - $NR^{65}C(O)$ - or -C(O) NR^{65} -; wherein R^{65} and R^{66} are independently selected from hydrogen or C_{1-6} alkyl, and x is 0-2;

R^{63} and R^{67} are independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxy, methylamino, dimethylamino, *N*-methylcarbamoyl,

5 *N,N*-dimethylcarbamoyl, methylthio, methylsulphinyl, mesyl, *N*-methylsulphamoyl and *N,N*-dimethylsulphamoyl; and

e, *f*, *g* and *h* are independently selected from 0-2;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

10 2. A compound of formula (I) according to claim 1 wherein M^1 is $-CH_2-$ and M^2 is $-CR^{22}R^{23}-$; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

3. A compound of formula (I) according to claim 1 wherein M^1 is $-CH_2-$ and M^2 is
15 $-NR^{24}-$; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

4. A compound of formula (I) according to claim 1 or 2 wherein R^{22} and R^{23} are
20 independently selected from hydrogen and hydroxy; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

5. A compound of formula (I) according to claim 1 or 3 wherein R^{24} is hydrogen; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

25 6. A compound of formula (I) according to any one of claims 1-5 wherein R^1 and R^2 are C_{1-4} alkyl; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

7. A compound of formula (I) according to any one of claims 1-6 wherein *v* is 0; or a
30 pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

8. A compound of formula **(I)** according to any one of claims 1-7 wherein R^4 and R^7 are hydrogen; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
- 5 9. A compound of formula **(I)** according to any one of claims 1-8 wherein the R^5 or R^6 not selected from a group of formula **(IA)** is hydrogen or methylthio; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
10. A compound of formula **(I)** according to any one of claims 1-9 wherein one of R^5 and
10 R^6 is a group of formula **(IA)** (as depicted above); wherein:
Z is -O- or -S(O)_b-; wherein b is 0;
 R^8 is hydrogen;
 R^9 is hydrogen;
 R^{10} and R^{11} are independently selected from hydrogen or carbocyclyl; wherein R^{10} and
15 R^{11} may be independently optionally substituted on carbon by one or more substituents
selected from R^{28} ;
 R^{13} is a group of formula **(IB)** (as depicted above);
 R^{14} is hydrogen;
 R^{15} is hydrogen;
20 R^{17} is C₁₋₁₀alkyl; wherein R^{17} may be optionally substituted on carbon by one or more
substituents selected from R^{47} ; or R^{17} is a group of formula **(IC)** (as depicted above) wherein:
 R^{18} is selected from hydrogen;
 R^{19} is selected from hydrogen;
 R^{20} is C₁₋₁₀alkyl; wherein R^{20} may be independently optionally substituted on carbon
25 by one or more R^{57} ;
p is 1;
q is 0;
r is 0;
m is 0;
30 n is 1;
z is 1; and
 R^{28} , R^{47} and R^{57} are independently selected from halo and hydroxy

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

11. A compound of formula (I) wherein:

M^1 is $-\text{CH}_2-$;

5 M^2 is $-\text{CR}^{22}\text{R}^{23}-$ and $-\text{NR}^{24}-$;

R^{22} and R^{23} are independently selected from hydrogen and hydroxy;

One of R^1 and R^2 is ethyl and the other is butyl;

v is 0;

R^4 and R^7 are hydrogen;

10 One of R^5 or R^6 is selected from a group of formula (IA) (as depicted above) and the other is hydrogen or methylthio;

Z is $-\text{O}-$ or $-\text{S}(\text{O})_b-$; wherein b is 0;

R^8 is hydrogen;

R^9 is hydrogen;

15 R^{10} and R^{11} are independently selected from hydrogen, 2-fluorophenyl or carbocyclyl;

R^{13} is a group of formula (IB) (as depicted above);

R^{14} is hydrogen;

R^{15} is hydrogen;

R^{17} is pentyl substituted by 5 hydroxy; or R^{17} is a group of formula (IC) (as depicted

20 above) wherein:

R^{18} is selected from hydrogen;

R^{19} is selected from hydrogen;

R^{20} is pentyl substituted by 5 hydroxy;

p is 1;

25 q is 0;

r is 0;

m is 0;

n is 1; and

z is 1;

30 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

12. A compound of formula (I) selected from:

(+/-)-trans-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

(+/-)-trans-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

1,1-dioxo-3-ethyl-3-butyl-4-hydroxy-5-phenyl-7-(*N*-{ α -[*N'*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-2-fluorobenzyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine; or


10 1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(*N*-{1-[*N'*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-1-(cyclohexyl)methyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.


15 13. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in anyone of claims 1-12, which process (wherein variable groups are, unless otherwise specified, as defined in claim 1) comprises of:

Process 1): for compounds of formula (I) wherein Z is -O-, -NR^a or -S-; reacting a compound

20 of formula (IIa) or (IIb):




(IIa)



(IIb)


with a compound of formula (III):




(III)

wherein L is a displaceable group;

Process 2): reacting an acid of formula (IVa) or (IVb):




(IVa)




(IVb)

or an activated derivative thereof; with an amine of formula (V):




(V);

10 *Process 3*): for compounds of formula (I) wherein R¹³ is a group of formula (IB); reacting an acid of formula (VIa):




(VIa)

or (VIb):



(VIb)


with an amine of formula:



(VI)


5

Process 4): for compounds of formula (I) wherein R^{13} is a group of formula (IB) and R^{17} is a group of formula (IC); reacting an acid of formula (VIIIa):




(VIIIa)

10 or (VIIIb)



(VIIIb)


or an activated derivative thereof; with an amine of formula (IX):




5

(IX)

Process 5) for compounds of formula (I) wherein one of R⁵ and R⁶ are independently selected from C₁₋₆alkylthio optionally substituted on carbon by one or more R²⁵; reacting a compound of formula (Xa) or (Xb):



(Xa)



(Xb)

10

wherein L is a displaceable group; with a thiol of formula (XI):



(XI)

wherein R^m is C₁₋₆alkylthio optionally substituted on carbon by one or more R²⁵;

15 and thereafter if necessary or desirable:

i) converting a compound of the formula (I) into another compound of the formula (I);

- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug.

14. A compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate
5 of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 12 for use as a
medicament.

15. A compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of
such a salt or a prodrug thereof, as claimed in any one of claims 1 to 12 for use in a method of
10 prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

16. The use of a compound of the formula (I), or a pharmaceutically acceptable salt,
solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 12 in
the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a
15 warm-blooded animal, such as man.

17. A method for producing an IBAT inhibitory effect in a warm-blooded animal, such as
man, in need of such treatment which comprises administering to said animal an effective
amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate
20 of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 12.

18. A pharmaceutical composition which comprises a compound of formula (I), or a
pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as
claimed in any one of claims 1 to 12, in association with a pharmaceutically-acceptable
25 diluent or carrier.

19. A combination comprising a compound of formula (I), or a pharmaceutically
acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of
claims 1 to 12, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt,
30 solvate, solvate of such a salt or a prodrug thereof.

20. A combination comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 12, and a bile acid binder.

5 21. A combination comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 12, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder.

10 22. A combination according to claim 19 or claim 21 wherein the HMG Co-A reductase inhibitor is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

23. A combination according to claim 19 or claim 21 wherein the HMG Co-A reductase
15 inhibitor is rosuvastatin, or a pharmaceutically acceptable salt thereof.

24. A combination comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 12 and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt
20 thereof.

25. A composition according to claim 24 wherein the PPAR alpha and/or gamma agonist is (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl}ethoxy)phenyl]propanoic acid or a pharmaceutically acceptable salt thereof.

25

INTERNATIONAL SEARCH REPORT

PCT/GB2004/000695

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D281/10 C07D337/08 A61K31/38 A61K31/554 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, EMBASE, BIOSIS, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 03/022825 A (ASTRAZENECA UK LTD ; ASTRAZENECA AB (SE); BLOMBERG DAVID (SE); STARKE) 20 March 2003 (2003-03-20) cited in the application method 2, example 2	1,3,5-9
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAGASE, TOSHIO ET AL: "Preparation of benzothiazepine derivatives with activity of bringing about high blood GLP-1 concentration" XP002288326 retrieved from STN Database accession no. 2002:521715 abstract -/-	1,3,5, 7-9,14, 15,18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

21 July 2004

Date of mailing of the international search report

05/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

PCT/GB2004/000695

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	-& WO 02/053548 A1 (BANYU PHARMACEUTICAL CO., LTD., JAPAN) 11 July 2002 (2002-07-11) examples 1167,1275	
Y	WO 02/08211 A (NEUMANN WILLIAM L ; G D SEARLE LLC (US); KOELLER KEVIN J (US); TREMONT) 31 January 2002 (2002-01-31) the whole document	1-25
Y	WO 00/47568 A (KOLODZIEJ STEVE A ; TOLLEFSON MICHAEL B (US); REITZ DAVID B (US); SEAR) 17 August 2000 (2000-08-17) cited in the application the whole document	1-25
Y	WO 00/01687 A (LEE LEN F ; REITZ DAVID B (US); SEARLE & CO (US); LI JINGLIN J (US); B) 13 January 2000 (2000-01-13) cited in the application the whole document	1-25
Y	WO 97/33882 A (LEE LEN F ; REITZ DAVID B (US); SEARLE & CO (US); LI JINGLIN J (US); B) 18 September 1997 (1997-09-18) cited in the application the whole document	1-25
Y	WO 96/05188 A (WELLCOME FOUND ; BRIEADDY LAWRENCE EDWARD (US)) 22 February 1996 (1996-02-22) cited in the application the whole document	1-25
Y	WO 96/08484 A (MONSANTO CO ; LEE LEN FANG (US); MILLER RAYMOND EUGENE (US); TREMONT S) 21 March 1996 (1996-03-21) cited in the application the whole document	1-25
A	LEWIS M C ET AL: "EFFECTS OF 2164U90 ON ILEAL BILE ACID ABSORPTION AND SERUM CHOLESTEROL IN RATS AND MICE" JOURNAL OF LIPID RESEARCH, BETHESDA, MD, US, vol. 36, no. 5, May 1995 (1995-05), pages 1098-1105, XP000908869 ISSN: 0022-2275 the whole document	1-25
A	EP 0 864 582 A (HOECHST AG) 16 September 1998 (1998-09-16) cited in the application abstract; claims	1-25

INTERNATIONAL SEARCH REPORT

PCT/GB2004/000695

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 17 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB2004/000695

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03022825	A	20-03-2003	CA 2459457 A1 EP 1427713 A1 WO 03022825 A1	20-03-2003 16-06-2004 20-03-2003
WO 02053548	A1	11-07-2002	NONE	
WO 0208211	A	31-01-2002	US 2002183307 A1 AU 8081001 A WO 0208211 A2 US 2004077625 A1	05-12-2002 05-02-2002 31-01-2002 22-04-2004
WO 0047568	A	17-08-2000	AU 3694600 A CA 2362147 A1 CN 1346351 T EP 1155007 A2 HU 0105409 A2 JP 2002536440 T WO 0047568 A2 ZA 200106252 A	29-08-2000 17-08-2000 24-04-2002 21-11-2001 29-05-2002 29-10-2002 17-08-2000 30-07-2002
WO 0001687	A	13-01-2000	US 5994391 A AT 256122 T AU 766957 B2 AU 4820299 A BG 105206 A BR 9911737 A CA 2336315 A1 CN 1312805 T DE 69913530 D1 DK 1091953 T3 EE 200100002 A EP 1091953 A1 HR 20010004 A1 HU 0102840 A2 ID 28221 A JP 2002519418 T NO 20010016 A NZ 509621 A PL 346324 A1 PT 1091953 T SI 1091953 T1 SK 20302000 A3 TR 200100824 T2 WO 0001687 A1 US 6107494 A US 6262277 B1 US 2002013476 A1 ZA 200100028 A	30-11-1999 15-12-2003 30-10-2003 24-01-2000 28-09-2001 11-12-2001 13-01-2000 12-09-2001 22-01-2004 13-04-2004 17-06-2002 18-04-2001 31-12-2001 28-01-2002 10-05-2001 02-07-2002 02-03-2001 29-08-2003 11-02-2002 30-04-2004 30-06-2004 06-11-2001 23-07-2001 13-01-2000 22-08-2000 17-07-2001 31-01-2002 25-07-2001
WO 9733882	A	18-09-1997	AU 723123 B2 AU 2326697 A BR 9708042 A CA 2248586 A1 CN 1221414 A ,B EP 0888333 A1 HU 9903047 A2 JP 2001526627 T NO 984146 A	17-08-2000 01-10-1997 27-07-1999 18-09-1997 30-06-1999 07-01-1999 28-05-2001 18-12-2001 30-10-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB2004/000695

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9733882	A	NZ 331813 A	30-03-2001
		RU 2202549 C2	20-04-2003
		US 6268392 B1	31-07-2001
		US 2004014803 A1	22-01-2004
		US 2003171426 A1	11-09-2003
		WO 9733882 A1	18-09-1997
		US 5994391 A	30-11-1999
		US 6107494 A	22-08-2000
		US 6221897 B1	24-04-2001
		US 6262277 B1	17-07-2001
		US 6420417 B1	16-07-2002
		US 2002013476 A1	31-01-2002
WO 9605188	A	22-02-1996	
		AP 720 A	08-01-1999
		AT 226946 T	15-11-2002
		AU 696073 B2	03-09-1998
		AU 4426096 A	07-03-1996
		BG 62048 B1	29-01-1999
		BG 101209 A	29-08-1997
		BR 9508586 A	14-07-1998
		CA 2197099 A1	22-02-1996
		CN 1161035 A ,B	01-10-1997
		CZ 9700373 A3	13-08-1997
		DE 69528704 D1	05-12-2002
		DE 69528704 T2	12-06-2003
		DK 775126 T3	03-03-2003
		EE 9700028 A	15-08-1997
		EP 1203769 A1	08-05-2002
		EP 0775126 A1	28-05-1997
		ES 2185711 T3	01-05-2003
		FI 970531 A	07-02-1997
		WO 9605188 A1	22-02-1996
		HK 1003936 A1	14-03-2003
		HU 77129 A2	02-03-1998
		IL 114877 A	14-07-1999
		JP 2935756 B2	16-08-1999
		JP 10504035 T	14-04-1998
		NO 970585 A	07-04-1997
		NZ 290911 A	28-07-1998
		OA 10597 A	22-08-2002
		PL 318496 A1	23-06-1997
		PT 775126 T	28-02-2003
		RU 2156245 C2	20-09-2000
		SK 17797 A3	10-09-1997
		ZA 9506647 A	10-02-1997
WO 9608484	A	21-03-1996	
		AT 199718 T	15-03-2001
		AU 700557 B2	07-01-1999
		AU 3373695 A	29-03-1996
		BR 9508916 A	30-12-1997
		CA 2199944 A1	21-03-1996
		CN 1162311 A ,B	15-10-1997
		DE 69520364 D1	19-04-2001
		DE 69520364 T2	13-09-2001
		DK 781278 T3	17-04-2001
		EP 0781278 A1	02-07-1997
		ES 2155136 T3	01-05-2001
		GR 3035583 T3	29-06-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB2004/000695

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9608484	A	JP 10505830 T	09-06-1998
		JP 3304093 B2	22-07-2002
		PT 781278 T	30-08-2001
		US 6268392 B1	31-07-2001
		US 2004014803 A1	22-01-2004
		US 2003171426 A1	11-09-2003
		WO 9608484 A1	21-03-1996
		US 5994391 A	30-11-1999
		US 6107494 A	22-08-2000
		US 6262277 B1	17-07-2001
		US 6420417 B1	16-07-2002
		US 2002013476 A1	31-01-2002
EP 0864582	A	16-09-1998	
		EP 0864582 A2	16-09-1998
		AT 242258 T	15-06-2003
		AU 731575 B2	05-04-2001
		BR 9801126 A	21-03-2000
		CA 2231971 A1	14-09-1998
		CN 1194979 A , B	07-10-1998
		CZ 9800759 A3	16-09-1998
		DE 69815180 D1	10-07-2003
		DE 69815180 T2	29-04-2004
		DK 864582 T3	29-09-2003
		ES 2198613 T3	01-02-2004
		HU 9800541 A2	28-06-1999
		ID 20053 A	17-09-1998
		IL 123648 A	21-11-2000
		JP 3282998 B2	20-05-2002
		JP 10279568 A	20-10-1998
		NZ 329932 A	28-01-1999
		PL 325363 A1	28-09-1998
		PT 864582 T	31-10-2003
		RU 2179977 C2	27-02-2002
		TR 9800444 A2	21-10-1998
		US 6020330 A	01-02-2000
		US 6114322 A	05-09-2000
		ZA 9802140 A	14-09-1998